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Rheumatoid arthritis (RA) is an autoimmune condition that causes chronic joint pain and 
destruction. The current standard regimen of monotherapy disease modifying anti-
rheumatic drug (DMARD) treatments may not be as effective as that of combination 
therapy of a DMARD and a biologic agent in treating RA. The purpose of this study was 
to answer the question, is there a difference in the therapeutic efficacy of combination 
DMARD treatments with a biologic, compared to monotherapy DMARDs without a 
biologic, in U.S. Caucasian women between the ages of 30 and 60 that have been 
diagnosed with RA? Guided by the theoretical framework of integrated theory from 
evidence-based practices, this study used a cross sectional study design and data from 
AR-PoWER Patient Powered Research Network. Having adjusted for age, logistic 
regression was used to examine the association between the therapeutic effectiveness and 
treatment modality (DMARDs without a biological agent versus DMARDs with a 
biologic agent; OR = 1.15, 95% CI = 0.57-2.33). The result indicated that there was no 
significant association between treatment effectiveness and treatment modality. A 
positive social change implication of this finding is that the assessment of the efficacy of 
DMARDs with or without a biologic agent may warrant further investigation in which 
studies with large sample sizes that include various populations are used. In this study, 
there was no difference between the monotherapy and combination therapy treatments for 
Caucasian women aged 30 to 60 years. However, a future study with a larger sample size 
that compares diverse populations may produce a different outcome. 
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Chapter 1: Introduction to the Study 
Background 
Rheumatoid arthritis (RA) is a chronic autoimmune disorder that causes abnormal 
inflammation of the joints (Zengin et al., 2018). It can attack organs such as the heart and 
the lungs, tissues such as muscle and cartilage, and ligaments and bone (Shiel, 2018). RA 
causes chronic swelling that results in permanent joint destruction and severe pain (Shiel, 
2018). The aggressiveness of this disease can cause permanent disability (Shiel, 2018). 
An estimated 23.5 million United States citizens have been affected by the autoimmune 
effects of RA (Alam et al., 2017). The disease is estimated to be 2-3 times more common 
in women than men (Bokarewa, 2014). RA can affect all ages and races (Shiel, 2018). 
RA is known to shorten the lifespan of patients and increase their risk of mortality (Kelly 
& Hamilton, 2007). One of the common treatment options for RA is the use of disease-
modifying, anti-rheumatic drugs (DMARDs), but these treatments are still observed to be 
less effective than combination treatments with a biologic in reducing the risk of 
mortality due to their suppression of the immune system by targeting the entire system 
(Iliades, 2017). Researcher Chris Iliades (2017) observed Janus Kinases (JAK) pathways 
for a broad population that included all races and genders. His study showed that 
DMARDs were less effective than combination treatments. Because combination 
treatments have not been observed at specific population levels, this study observed 
Caucasian women from ages 30 to 60 years. Combination treatments can include other 
DMARDs or the use of biologics. Biologics, such as tumor necrosis factor (TNF) 





inflammatory process (Iliades, 2017), whereas DMARDS inhibit the production of 
cellular immune response to antigens. There are biologics that target other immune 
pathways, such as interleukin pathways and JAK pathways, which was the pathway that 
Iliad studied. 
Problem Statement 
The therapeutic efficacy of combining DMARDs and biologics has never been 
comprehensively studied at population data levels of Caucasian Alabamian women aged 
30 to 60 years who have been diagnosed with RA. Biologics may work well in 
combination with DMARDs, such as Plaquenil or methotrexate, that interfere with cell 
communication in autoimmune diseases by hindering the antigen processing (Goldman et 
al., 2000). These immunosuppressants can help prevent infection by reducing the 
frequency of producing antibodies to the biologic agent (Cunha, 2016). Adequate 
research has not been performed to provide data on the effectiveness of combination 
treatments with a DMARD and a biologic. Therefore, further research is needed on the 
comparative analysis of combination treatments with and without biologic agents 
(Gradual et al., 2014). The importance of this study was that it compared the results 
obtained in the target population when using a DMARD with and without a biologic. 
Methotrexate is the standard first choice treatment of physicians and insurance providers. 
Insurance companies may require patients to have a trial and failure on this drug before 
they can move to another DMARD treatment, such as Plaquenil, or a biologic. The 





population of U.S. citizen women aged 30 to 60 years collected from a national database 
through statistical data analysis. The DMARDs work by stopping inflammatory cells 
from being produced, and the biologics work to stop the immune system from being 
overactive, and together the two may shorten the disease progression and allow the 
patient to feel pain relief in a timely manner (Levine, 2017).  
Purpose of the Study 
The purpose of the study was to compare the therapeutic efficacy of RA 
treatments, a DMARD, such as Plaquenil or methotrexate, which are the most commonly 
used DMARDs, with and without a biologic, in a specific population. This study used a 
cross sectional study design and data from Arthritis Partnership with Comparative 
Effectiveness Researchers (AR-PoWER), a Patient Powered Research Network. Having 
adjusted for age, logistic regression was used to examine the association between the 
therapeutic effectiveness and treatment modality (DMARD with and without a biologic.)  
The typical challenges of research on population data are time, expense, and clinical 
conditions. The plan to control for these challenges is the establishment of a target 
population and written approvals to access national databases. The target population for 
this research was specifically gender-based and population-based. It included Caucasian 
women that are United States Citizens, aged 30 to 60 years, because RA is most common 
in women between those ages (Arthritis Foundation, 2017). It is of high importance to 





sustaining overall improvement and wellbeing of the patients (National Rheumatoid 
Arthritis Society [NRAS], 2019). 
Significance of the Study 
This study enhanced the knowledge on how DMARD treatments could be used in 
conjunction with a biologic to control for the inflammatory responses to prevent pain, 
severe bone erosion, joint deformity, and organ damage (Guo et al., 2018). Combination 
treatments can be effective for some RA patients but are not necessarily effective for all 
RA patients, because the prescribed treatments for the autoimmune disease will respond 
to each individual’s cellular structure differently. There was a knowledge gap between 
the use of DMARD monotherapy versus combination biologic-DMARD therapy for the 
therapeutic efficacy of RA treatments, but this study provided knowledge that helped 
close the gap for Caucasian women aged 30 to 60 years that have been diagnosed with 
RA. The statistical findings were that a DMARD and biologic work together to provide 
relief to the patient with RA, but not necessarily better than DMARDs alone. In some 
patients, an early diagnosis together with a combination therapy could provide relief by 
suppressing the inflammation and blocking the inflammatory pathway in a shorter time 
frame than monotherapy treatments because biologics cause cells to respond quicker than 
DMARDs (Rein & Mueller, 2017). A combination drug treatment, such as a Plaquenil 
DMARD and a Remicade biologic, may seem to be an effective therapy, considering 
DMARDs work by stopping inflammatory cells from being produced, and the biologics 





findings of this study did not support the therapeutic efficacy of the two treatments taken 
in conjunction. This research was performed to fill the gap in the literature as to whether 
combination therapy consisting of a DMARD and a biologic should be the initial 
standard drug treatment for U.S. Caucasian women between the ages of 30 to 60 years 
that have been diagnosed with RA. Public health practitioners, insurance providers and 
physicians are the ones that design the policies of standard regimen for the disease. This 
research can possibly make an impact on their policies of treatments for patients being 
diagnosed with RA.  
This study did not find that combination therapy is better than the current standard 
monotherapy, but it may continue to cause social change through statistical evidence that 
a combination treatment could be used to decrease the severity of joint pain for some 
patients, but is not statistically therapeutic for all patients to control the pain ailments and 
disability that occur with RA. This study may help bring social change by providing 
evidence related to the efficacy of combination therapy for RA, compared to the standard 
monotherapy treatment, which would be valuable in developing more effective clinical 
and/or public health practices for healthcare policy regulations to ensure regulatory 
standards are being met. A social change implication of this study’s findings is that the 
assessment of the efficacy of DMARDs with a biologic agent and DMARDs without a 
biologic agent may warrant further investigation in studies with large sample sizes that 





Rationale of Theoretical Framework  
The use of integrated theory from evidence-based practices uses data from 
patients that details their effectiveness of the drug treatments that would allow for more 
accurate decision making to be made in comparing monotherapy and combination 
therapy for RA patients. Integrated theories are based on evidence in research 
(Gopalakrishnan & Ganeshkumar, 2013). Integrated theories make connections through 
knowledge and practice. Integrated theory from evidence-based practice is customarily 
used to examine intervention efficacy and safety (Pipe, 2017) and is adopted as an 
appropriate framework for guiding the comparison of therapeutic efficacy of RA 
treatments. There are particular areas of interest for the use of integrated research, such as 
epidemiology, health promotions, health risk factors, clinical pathology, preclinical 
biology and disease mechanisms, and models in medicine and biosciences (National 
Research Council, 2018). Stakeholders that would be interested in using the integrated 
research model would be clinicians, scientists, health providers, pharmaceuticals, and 
bio-tech industries (National Research Council, 2018). The research model targets 
tailored care, better quality of life, and healthcare maintenance and promotion (National 
Research Council, 2018). The end users of the research model are the patients that benefit 
from the therapeutics (National Research Council, 2018). This proposed research 
framework has the potential to inspire questions and challenge method assumptions (Din 





Quantitative Research Question 
Is there a difference in the therapeutic efficacy of combination DMARD 
treatments with a biologic, compared to monotherapy DMARDs without a biologic, in 
U.S. Caucasian women between the ages of 30 and 60 that have been diagnosed with 
RA? 
This study was conducted as quantitative research. It consisted of secondary data 
for comparative analysis. The possible differences in the variables were the focus of the 
exploration. The goal was to reveal a variation of differences in the forms of treatments 
as the basic formation of statistical analysis. It was beneficial to determine the statistical 
impact of the variables: DMARD therapy without a biologic, in comparison to the 
DMARD with a biologic. 
Null Hypothesis: There is no difference in the therapeutic efficacy between 
combination therapy and monotherapy in treating U.S. Caucasian women between the 
ages 30 and 60 that have been diagnosed with RA. 
Alternative Hypothesis: There is a difference in the therapeutic efficacy between 
combination therapy and monotherapy in treating U.S. Caucasian women between the 
ages 30 and 60 that have been diagnosed with RA. 
Definition of Terms 
 Antigen: A molecule in the body that triggers an adaptive immune response. 
(Arduengo, 2020). In reference to autoimmunity, the antigen is a self-antigen that triggers 





 Articular: The synovial joints (Bhosale & Richardson, 2008). 
Autoimmune: A self-damaging condition in which the cells mistakenly attack the 
body in response to a malfunction of the immune system (Zengin et al., 2018).  
Biologic Agents: Drugs that are complex medicinal products from living 
organisms. This class of drugs is used to treat a variety of diseases, including 
autoimmune diseases, cancer, growth disorders, and rare genetic conditions (Cunha, 
2016).  
Clinical Conditions: The identification of a patient’s diagnosis that is associated 
with one specific health condition or more than one health condition (Tilea et al., 2018).  
Disease-modifying antirheumatic drugs: A class of drugs made of monoclonal 
antibodies that are used to treat RA, as well as other autoimmune diseases, to suppress 
joint damage, induce or maintain remission, reduce flare-ups, and sustain disease control 
(Guo et al., 2018).   
Immunogenicity: The ability of an antigen to trigger a cell-mediated immune 
response (Sauna, 2020).  
Immunosuppressants: A class of drugs used for autoimmune diseases to weaken 
the immune system to suppress the damaging reaction that is being induced on the body 
by its own cellular activity (Cunha, 2016).  
Methotrexate: A folic acid analogue drug that is used as a chemotherapeutic agent 
in the treatment of RA and other autoimmune diseases as well as cancer (Teja & 





Plaquenil: An anti-inflammatory, hydroxychloroquine (HCQ) drug that is used as 
a suppressive treatment for RA and lupus, and it is also used against malaria (American 
College of Rheumatology, 2018). It interrupts cellular communication of the immune 
system to prevent joint damage and reduce the risk of long-term disability (American 
College of Rheumatology, 2018).  
Population Data: Information gathered from a specific group or population 
identified by characteristics for data. In this research it is women with RA (Taylor et al., 
2019). 
Rheumatoid Arthritis: A chronic autoimmune disorder that causes abnormal 
inflammation of the joints (Zengin et al., 2018). 
Suppress: The reduction or inhibition of a  
 reaction of the immune system (Cunha, 2016). 
 Synovial: A secreted membrane fluid that lubricates the joints (Bhosale & 
Richardson, 2008). 
Therapeutic Efficacy: The maximum response of a drug to achieve beneficial 
therapy/treatment (Mandal, 2018). 
Tumor Necrosis Factor: A protein that is capable of inducing apoptosis, cell 
death, of a tumor cell through pro-inflammatory actions (Shiel, 2019). Cytokines are the 






Tumor Necrosis Factor-IR (TNF-IR): Patients who exhibit inadequate response to 






Chapter 2: Literature Review 
Introduction 
RA is a common chronic autoimmune disease with disabling joint inflammation. 
The inflammatory disease causes chronic pain, stiffness, and swelling of the joints. It 
affects approximately 1% of the United States population and has an annual mortality 
rate of 26 per 1000 persons (95% CI, 25.87-27.97; Dellabella, 2018). The disease is twice 
as prevalent in women compared to men (Cherascu, 2011). The general range of affected 
ages are 40 to 70 years (Cherascu, 2011). However, all ages can be affected by RA.  
Patients suffering from RA endure chronic pain that can be localized to select 
body parts such as the knees or can be all over the body. The inflammation caused by the 
disease affects the tissues that surround the joints as well as other organs in the body 
(Kerkar, 2018). A person’s immune system attacks the healthy tissues of the body as if it 
were using antibodies to destroy invaders like pathogens that cause infections (Kerkar, 
2018). Therefore, patients diagnosed with this autoimmunity have antibodies in their 
blood that target the tissues of the body resulting in inflammation of the joints (Kerkar, 
2018). The chronic inflammation of the disease may result in damage to the bones, 
ligaments, and cartilage that leaves the joints deformed (Kerkar, 2018). The symmetrical 
arthritis of the smaller joints refers to the arthritis that attacks hands and feet (Cherascu, 
2011). However, bilateral arthritis attacks bilateral hand joints, which consist of 
interphalangeal joints (phalanges), metacarpophalangeal joints (knuckles), 





interphalangeal joints (phalanges), metatarsophalangeal joints (base of phalanges), 
tarsometatarsal joints (mid-foot), talonavicular joint (talus side of foot), and tibio-talar 
joint (ankle) (Arthritis Foundation, 2017). The larger joints that may be affected by the 
inflammatory processes are the shoulders, knees, hips, and axial skeleton (Cherascu, 
2011). The functional impairments of the disease result in the loss of productivity and an 
increase in disability (Cherascu, 2011). The disease can be so severe that it causes 
unrelenting joint destruction that can lead to amputation if not treated before the joint 
becomes deformed (Cherascu, 2011). 
Figure 1 
Rheumatoid Arthritis Deformity Example 
 








Risk Factors of RA 
RA causes chronic inflammation of the synovial membrane which lines the joints 
and connects the bone and cartilage (Jimenez-Boj et al., 2005). Thus, the joints are not 
the only part being injured as neighboring structures are also damaged (Jimenez-Boj et 
al., 2005). In fact, RA is capable of attacking all parts of the body, including the organs, 
bones, blood, and bone marrow. Specific organs and areas that may be affected by RA 
are the skin, lungs, heart, blood, eyes, mouth/gums, kidneys, liver, spleen, nervous 
system, bones, and bone marrow (Dunkin, 2015).  
Parts of the Body Affected by RA: 
1. Skin: Half of the patients with RA may develop rheumatoid nodules under the 
skin in bony areas that are exposed to pressure, the feet being a good example 
(Dunkin, 2015). These nodules are sensitive and can diminish or recede with 
DMARD treatment (Dunkin, 2015). Rashes and skin ulcers are capable of 
forming due to the underlying inflammation of the skin itself or the blood 
vessels (Dunkin, 2015). 
2. Lung: About 80% of the patients with RA experience lung inflammation that 
may cause interstitial lung disease and consequently shortness of breath 
(Dunkin, 2015). If persistent inflammation occurs, pulmonary fibrosis can 
develop, which is scarring of the lungs (Dunkin, 2015). The result is the 
thickening of the pulmonary wall and decreased oxygen. Rheumatoid nodules 





3. Heart: About 50% of the patients with RA experience inflammation of the 
heart lining known as pericarditis that results in chest pain (Dunkin, 2015). 
However, treatment with DMARD therapy and biologics can control the 
inflammation of the pericardium (Dunkin, 2015). Plaque from damaged blood 
vessels (atherosclerosis) can cause heart attack and strokes in patients with 
RA (Dunkin, 2015). DMARDs and biologics can reduce cardiovascular risks 
(Dunkin, 2015).  
4. Blood: Persistent inflammation can lead to a reduction of red blood cells thus 
causing anemia, which results in low-iron or low serum ferritin (Dunkin, 
2015). Inflammation of the blood and blood vessels can potentially cause 
blood clots by increasing the platelet counts (Dunkin, 2015).  
5. Eyes: RA patients are at risk of developing scleritis, which is an inflammation 
of the sclera of the eyes resulting in pain, redness, blurred vision, and light 
sensitivity (Dunkin, 2015). Another type of inflammation of the eyes is 
uveitis. The inflammation targets the area between the sclera and the retina 
and is capable of causing blindness without treatment (Dunkin, 2015). 
Inflammation can cause Sjogren’s syndrome, which damages the tear-
producing glands, resulting in severe dry and gritty eyes (Dunkin, 2015). 
6. Mouth/Gums: Inflammation of the moisture-producing glands in the mouth 
can lead to dry mouth and gum disease; bacteria can develop and cause tooth 





7. Kidneys: If a patient does not pursue a therapeutic regimen of DMARDs 
and/or biologics and chooses to treat RA with only non-steroidal anti-
inflammatory drugs (NSAIDS) to alleviate pain and swelling, damage to the 
kidneys may occur (Dunkin, 2015).  
8. Liver: Overuse of Tylenol and methotrexate therapy can result in liver 
damage (Dunkin, 2015).  
9. Spleen: Longstanding untreated RA can lead to Felty syndrome, which results 
in an enlarged spleen and low white blood cell counts (Dunkin, 2015). The 
condition increases the patient’s risks of bacterial infections, cancers, and 
lymphoma (Dunkin, 2015). 
10. Nervous System: Inflammation flares of tissues can lead to compression of 
nerves resulting in numbness and tingling (Dunkin, 2015). Carpal tunnel 
syndrome is a common concern with RA due to compressing of nerves by 
inflamed tissues of the wrist (Dunkin, 2015). The nervous system normally 
detects inflammation in the tissues, but RA can cause an imbalance in the 
nervous system (Koopman et al., 2016). RA reduces the activity of the 
parasympathetic nervous system and causes the sympathetic nervous system 
to become overactive (Koopman et al., 2016).  
11. Bones: RA causes chronic inflammation of the bones resulting in the loss of 





thin and brittle (Dunkin, 2015). DMARD therapy and biologic treatments can 
improve the bone condition.  
12. Bone Marrow: RA can infiltrate the bone marrow and disrupt the production 
of red blood cells (Bouchnita et al., 2016). This is consistent with the cause of 
anemia and lack of oxygen-binding proteins in the red blood cells.  
13. Cancer: RA is known to be associated with a number of cancers, including 
lymphoma, lung cancer, and non-melanoma skin cancer, and possibly 
cervical, prostate, and melanoma skin cancers, but a decreased risk of 
colorectal and breast cancers (Lange et al., 2016).  
Patients with RA have a shorter life expectancy than the general population 
mostly due to the significant increase in comorbidities such as heart attacks and strokes 
(Emrich, 2009). RA is commonly referred to as a systemic illness or rheumatoid disease 
since chronic inflammation affects multiple organs of the body (Kerkar, 2018). Vasculitis 
is one of the serious complications that results from RA (Cleveland Clinic, 2019). The 
comorbidity occurs when the blood vessels become inflamed. The arteries and veins may 
become weakened causing little or no blood flow to the skin, nerves, and internal organs 
(Cleveland Clinic, 2019). Vasculitis of the larger arteries that decreases or stops the blood 
flow to tissue sites can ultimately result in a stroke or heart attack (Cleveland Clinic, 
2019). Rheumatoid vasculitis occurs in the more severe RA cases. Patients who have 
suffered from RA for many years are likely to experience the illness (Cleveland Clinic, 





Inflammation and swelling of the heart’s outer wall or heart muscle itself is 
another serious complication among RA comorbidities. The swelling causes patients to 
experience chest pain and decreased cardiac output, which can lead to congestive heart 
failure (Emrich, 2009). The inflammation and swelling of the heart’s outer wall are called 
pericarditis (Emrich, 2009). Inflammation of the heart muscle is called myocarditis 
(Emrich, 2009). The two conditions weaken the functionality of the heart leading to 
congestive heart failure, which is a decrease in the pumping of the blood in and out of the 
heart. Although RA has high morbidity and mortality rates, it is often not the immediate 
cause of death but rather predisposes the patients to comorbidities that may directly cause 
death (Molina et al., 2015).  
Diagnosis of Rheumatoid Arthritis 
Through rheumatoid factor (RF) and anti-citrullinated protein antibody (tested as 
anti-cyclic citrullinated peptide [anti-CCP]), physicians, specifically rheumatologists, are 
able to establish the presence of the autoimmune disease (Cubero et al., 2016). Anti-CCP 
and RF are immunoglobulin M (IgM) antibodies produced by the immune system in 
response to foreign cells that produce inflammatory symptoms (Freeman, 2018). RF 
intensifies the inflammatory response of macrophages induced by the specific immune 
complexes of RA (Laurent et al., 2015). Citrullinated proteins are found in the synovial 
tissue, and they diminish amino acids such as arginine that change the charge of the 
protein which could potentially be a cause for the autoimmune disease because of its 





must interact with other proteins to function and communicate. Anti-CCPs are present in 
60- 70% of RA patients, and RF is present in 70- 90% of RA patients (Freeman, 2018). 
These markers can be found in early or late-stage disease (Freeman, 2018). The more 
aggressive the units of the lab results are for these tests, meaning the results exceed the 
normal range, can determine the aggression of the disease as well as a more aggressive 
treatment option (Freeman, 2018). These are specific biologic markers in the DNA that 
are associated with the pathogenesis of RA (Liao et al., 2009). The U.S. National 
Institutes of Health defined biomarkers as characteristic diagnostic indicators to measure 
the activity of the disease (Taylor, 2019). To fully diagnose a patient with RA, a positive 
anti-CCP blood test in conjunction with a positive RF along with physical examinations, 
imaging, and other blood tests that measure inflammation levels are required (Freeman, 
2018). However, x-rays may not show any signs of disease activity in early RA. On the 
other hand, inflammation and swelling are typically present on physical examination. 
Anti-CCP is used in conjunction with RF because RF alone can be present in other 
illnesses, such as hepatitis (Freeman, 2018). Therefore, the two biomarkers must be 
positive for a more accurate seropositive diagnosis of RA (Freeman, 2018). 
Autoimmune conditions like RA are mostly identified by autoantibodies. 
Autoantibodies are just like normal antibodies that are immune proteins created by the 
immune system, except autoantibodies mistakenly target the wrong cells or proteins as 
the antigen. RA patients might have a positive antinuclear antibody test result. The test is 





protein (CRP) and fibrinogen are immunological proteins produced by the liver (Babikir 
et al., 2017). They are used as biomarkers to monitor the status of inflammation in the 
body (Babikir et al., 2017). Erythrocyte sedimentation rate (ESR) is another blood test 
performed to check the inflammation in the body (Babikir et al., 2017). CRP and ESR 
levels mostly rise in RA, but they can also increase in other inflammatory diseases. The 
acute phase reactants formulate part of the RA classification process by serving as 
inflammatory markers (Aletaha et al., 2010). CRP and ESR levels help to measure RA 
disease activity and elicit medication response as well. 
Autoimmunity can cause disruptions and complications throughout the entire 
immune system. A decrease in the inflammatory articular disease reduces the 
autoantibodies being released that are attacking healthy cells. Besides, some ways have 
been used in differentiating RA from other arthritic disorders. Structural changes are seen 
using conventional radiography or the imaging methods used to distinguish RA from 
other arthritic disorders in their early stages. RA is less destructive in the early stages, but 
it accumulates over time by damaging bone, cartilage, and tissue. The longer RA is left 
untreated, the more damage it causes, which increases pain, deformity, and potential 
infections, and decreases lifespan.  
In the last 10 years, the process of fighting arthritic disorders has been done using 
DMARDs (Chatzidionysiou et al., 2017). The most commonly used DMARDs include 
methotrexate and Plaquenil. However, the development of new biological agents has 





of RA improves the likelihood of suppressing the disorder. In fact, early treatment of RA 
has saved patients from the severe effects of the disease. Current RA clinical treatment 
trials have been hindered by inadequate numbers of patients in the early stage of disease. 
Consequently, researchers have failed to establish the effectiveness of an early 
intervention therapy to prevent the progression of the disorder to later stages.  
Classification criterion is the standardized way of defining the presence of RA 
disorder in an individual. Taking the appropriate steps of diagnosing the disease by 
observing the specific markers doctors use to diagnose RA is classification criterion. 
However, careful clarification is involved because some markers can represent another 
autoimmune disease. For example, CRP and ESR are inflammatory markers for RA but 
can also be seen in Lupus. However, adequate elevation levels of RF and anti-CCP with 
ESR can represent autoimmunity for RA. Through the use of the classification method, 
healthcare personnel can group individuals by whether or not they have RA. Further, the 
grouping has helped in clinical trials on individuals who might be genetically receptive or 
who are already suffering from the disorder symptoms and being diagnosed. Again, the 
classification criteria have helped investigators to conduct various studies that relate to 
RA (Ajeganova et al., 2017). Through the research, scientists have managed to develop 
stringent measures of managing the disease. Doctors have applied the criteria in many 
parts of the world to address the effect and treatment of the disease. The American 
College of Rheumatology (ACR) came up with the classification criteria used commonly 





developed by the ACR are used in diagnosis to provide the benchmark for defining the 
presence of the condition. The classification criteria established by ACR distinguishes the 
afflictions of RA from other known rheumatology disorders, such as psoriatic arthritis.  
Etiology and Classification of RA 
Modern therapies aim to make sure RA patients do not go through the chronic 
stages of the disease as indicated in the 1987 criteria for RA disorder. However, experts 
from both ACR and the European League against Rheumatism (EULAR) came together 
to develop a more simplified way of approaching the diagnosis and treatment of RA 
disorder (Shiboski et al., 2017). The main aim of the ACR and EULAR experts was to 
devise classification criteria that would address methods of handling early cases of RA. 
The approach led to the development of the 2010 ACR/ EULAR classification criteria for 
RA.  
RA’s etiology remains multifactorial just like other autoimmune conditions; 
meaning it has various causes and influences. Familial clustering alongside monozygotic 
twin studies revealed genetic susceptibility with about half of RA risk being traceable to 
genetic factors (Chung et al., 2007). Genetic RA associations include human leukocyte 
antigen-DR45 and DRB1 among other alleles referred to as shared epitope (Chung et al., 
2007). Genome-wide studies pointed to other genetic signatures that raise the chances of 
acquiring RA and other autoimmune conditions, like cluster-of-differentiation-40 (CD40) 
and STAT4 gene (Chung et al., 2007). A cluster-of-differentiation (CD) surface protein 





cells, and B-cells. There is oxidative damage implicated in the pathogenesis of RA which 
causes an imbalance between the reactive oxygen and the biological system’s reaction to 
antioxidants (Karlson et al., 2008). Free radicals have been found within the rheumatoid 
synovium and in the plasma (Karlson et al., 2008). RA can be caused by environmental 
factors, such as long-term smoking and various infectious diseases, or it can be caused by 
genetic predisposition (Edwards & Cooper, 2006). Potential infectious candidates that 
could trigger this autoimmune response are retroviruses, Epstein-Barr Virus, Fifth 
Disease, Escherichia coli, Mycobacterium tuberculosis, and Proteus mirabilis (Edwards 
& Cooper, 2006). These infections can increase the antibody titers found in RA patients 
(Edwards & Cooper, 2006). Genetic factors are responsible for at least 50% of the risk, 
while environmental factors potentially make-up the rest (Edwards & Cooper, 2006).  
Individuals from families with genetic history of the disease, the elderly, and 
women are at a higher risk of the disease than those that are not of these categories. 
Gender and age differentials directly contribute to the disease prominence (Firestein & 
Kelley, 2009). Current and previous cigarette smokers have higher chances of contracting 
RA (Costenbader et al., 2006). Pregnancy is known to cause RA remission due to 
immunologic tolerance (Kaaja & Greer, 2005). Parity exhibits a long-lasting impact, and 
it is notable that RA is less likely to occur among pregnant women compared to 
nulliparous women (Guthrie et al., 2010). However, during pregnancy there is a spike of 
estrogen and progesterone. Hormones can play a huge role in woman in various ways. 





disease. Recently, researchers Grant Hughes and Divaker Choubey studied the hormonal 
effect on RA (Lunardo, 2016). They found that at high levels, these two hormones 
suppress RA, such as during pregnancy, but at lower levels, such as during menopause, 
hormone replacement and oral contraceptives are associated with a greater risk of RA 
(Lunardo, 2016). More research is required on the hormonal effect of RA, but researchers 
have confirmed that estrogen and progesterone are “dominant risk modulators” for a 
similar autoimmune disease called Lupus (Lunardo, 2016). A risk of disease production 
through breastfeeding was a concern until a recent study was performed and found that 
long-term breastfeeding of greater than 13 months was associated with a significant 
reduction of RA (Liao et al., 2009). Therefore, breastfeeding reduces the chances of 
advancing to RA among women who breastfeed. High birthweight is a potential risk 
factor for RA. A recent study focused on this risk and found that babies weighing greater 
than 9.9lbs at birth had at least a two-fold risk of developing RA compared with babies 
who were 7.0 - 8.5lbs at birth (Liao et al., 2009). The disease is high during menstrual 
cycles and intermittent menstrual periods; increasing the woman’s risk of advancing to 
RA (Karlson et al., 2004). The hormone changes that occur during menstrual cycles 
disrupt the inflammatory markers in the body causing flare-ups of RA. 
RA creates inflammatory pathways that result in synovial cell proliferation within 
the joints. Over secretion of proinflammatory cytokines like TNF, JAK and interleukin-6 
(IL-6) makes the destruction process take place quickly (Scott et al., 2010). TNF is a 





inflammatory actions (Shiel, 2019). Elevated levels of IL‐6 have been reported in the 
serum and synovial fluid of RA patients and found to correlate with inflammation and 
disease activity (Genovese, Fleischmann & Kivitz, 2015). A humanized inhibitor of IL‐6 
activity has been shown to be elevated in RA, but an administered combination of 
therapeutics with a DMARD and a biologic may reduce the pro-inflammatory cytokine 
(Genovese et al., 2015). Cytokines are expressed at high levels in the joint tissues 
resulting in inflammation and articular destruction (Taylor & Feldman, 2009). “TNF was 
the first cytokine to be fully validated as a therapeutic target for RA” (Taylor & Feldman, 
2009). Although TNF is the preferred target for biologic therapy, interleukins have also 
been validated for target therapy (Taylor & Feldman, 2009).  
Patients diagnosed with RA mostly exhibit pain and stiffness across various joints 
of the body. The most affected joints are proximal interphalangeal joints, wrists, and 
metatarsophalangeal joints. Morning stiffness that lasts beyond an hour could be a form 
of inflammatory etiology. Dreadful swelling from synovitis becomes visible at any stage. 
The subtle synovial thickening might be palpable when examined. Before the onset of 
clinically diagnosable swelling, the patient might develop indolent arthralgias. Systemic 
symptoms like fatigue, low-grade fever, and weight loss might occur once the disease 
fully develops or matures. 
ACR and EULAR worked together in 2010 to establish newly distinct 
classification measures for RA (Aletaha et al., 2010). The newer techniques express 





classification criteria through observation of specific protein markers and magnetic 
resonance imaging (MRI) of bone erosion. Moreover, a group of Dutch researchers 
developed clinical prediction rules for RA (Van der Helm-van Mil et al., 2007; Mochan 
& Ebell, 2008) whose purpose was to identify patients with undifferentiated arthritis that 
could potentially develop RA. As a result, this standard involves follow-up and referral 
processes. After doctors diagnosed a patient with RA there were standards for follow-up 
appointments to re-evaluate the progress of the disease and the effectiveness of the 
medications. If a doctor was not able to make an accurate diagnosis, then a referral was 
performed. It is best to see an actual rheumatologist for evaluation of RA opposed to 
general physicians because the rheumatologists are more knowledgeable of the 
biomarkers to evaluate.  
Immunology Alongside RA 
The understanding of the pathophysiological aspects of RA is difficult. There is 
evidence that RA plays a pivotal role on the immune response, but researchers 
understanding of the disease is far from complete (Kavanaugh & Lipsky, 2012). The 
immune system responds when it is activated by antigens that may include proteins being 
seen as antigens. For people with RA, their immune system is activated consistently due 
to an immune response of releasing cytokines, interleukins, and TNF in response to 
healthy cells that are foreseen as antigens. As a result of the autoimmunity activating an 
immune response, the body becomes weak and exhausted. There have been vigorous 





therapeutic agents and improved therapies (Kavanaugh & Lipsky, 2012). The molecular 
design to treat the damaging immunological responses caused by RA is to target specific 
parts of the immune system that are responsible for the reaction without causing further 
damage to the filtering organs (Kavanaugh & Lipsky, 2012). The primary complete blood 
count alongside the differential and assessment of the hepatic and renal functions 
fundamentally assists in determining the treatment options. For instance, patients that 
suffer from insufficient renal function or significant thrombocytopenia would not be 
prescribed a NSAID due to an increase in renal toxicity. Of those RA patients that 
experienced problems or difficulty with their hemoglobin levels or hepatic functions, 33-
60% incurred chronic mild anemia (Wilson et al., 2004). This is due to a drop in red 
blood cells and the reduction of oxygen needed to be transferred to functioning organs 
that make proteins important for fighting infection and inflammation (Wilson et al., 
2004). Gastrointestinal blood loss should be prevented among patients on NSAIDs or 
corticosteroids. Methotrexate is not recommended for patients with hepatitis C or severe 
renal impairment (Saag et al., 2008) because methotrexate can elevate liver enzymes 
which can leak chemicals into the blood stream and cause toxicity to the blood (Kassas et 
al., 2018). Biological agent therapies deserve negative tuberculin tests that tests for latent 
tuberculosis (TB) because TNF inhibitors interfere with immune system allowing for 
infections to occur, and TB is still active today. The TNF inhibitors are used for 
autoimmunity, but the potency of the medication can interfere with immune responses. 





because the DMARDS suppress the immune system to reduce the frequency of producing 
antibodies to the biologic (Cunha, 2016). Hepatitis B reactivation is a possible occurrence 
with TNF inhibitor use. Patients whose symptoms are of less than six weeks duration 
might experience viral processes like parvovirus (Saag et al., 2008). Recurrent self-
limited episodes of acute joint swelling predict crystal arthropathy, which means 
arthrocentesis ought to be performed to assess calcium pyrophosphate dehydrate or 
monosodium urate monohydrate crystals (Saag et al., 2008). To assist in conducting 
diagnosis and possible choice of a given treatment strategy, patients with inflammatory 
arthritis may get a prompt referral to rheumatology subspecialists to check characteristics 
of given erosive changes. Hands and feet radiography should be performed to assess 
patients who exhibit inflammatory back symptoms, inflammatory eye disease, or 
inflammatory bowel disease that might depict spondyloarthropathy (Saag et al., 2008). 
Skin findings, such as rashes that suggest systemic lupus erythematosus, systemic 
sclerosis, or psoriatic arthritis, may be the cause of the rashes from an autoimmune 
reaction (Wilson et al., 2004). Polymyalgia rheumatic are typically considered among 
older patients incurring symptoms within their hips and shoulder; and these patients 
should be asked questions based on temporal arteritis. Various myofascial trigger points 
and somatic symptoms predict possible fibromyalgia that may exist alongside RA. There 
may be multiple immune-mediated conditions that seem to follow the autoimmune 





Efficacy-Based Treatment Guidelines for Rheumatoid Arthritis 
The main treatment guidelines for RA suggest the use of DMARDs as the 
mainstay therapeutic intervention for the disease. DMARDs should be administered 
immediately after diagnosis to treat the condition. Early diagnosis and drug therapy using 
DMARDs may help prevent structural damage, and may lead to possible remission 
(Cherascu, 2011). The sooner the diagnosis, the sooner the treatments begin. Once the 
treatments become active, the desirable outcome will entail reduced pain and 
inflammation as well as the prevention of further destruction of the body by the disease. 
Medical practitioners should begin administering the therapy to patients with RA, 
who are at risk of erosive and persistent arthritis, even if they do not meet the prescribed 
benchmarks for initiating the treatment. It is not absurd to start the treatment with 
DMARDs before confirmation of diagnosis. Because RA takes time to diagnose, there 
are outcomes of good quality randomized controlled trials (RCT) that give evidence of a 
possible role of therapeutic drugs in undistinguished arthritis (Wilson et al., 2004). These 
RCTs may prevent progression of radiographic damage of joint destruction and anemia 
through trial and error of research (Wilson et al., 2004). The mission of the treatment is to 
aim for a target. The target may be remission or low disease activity (Craven, 2017). The 
disease activity may be monitored every 1-3 months (Craven, 2017). If there is not any 
improvement by the 3rd month of treatment, then the physician may adjust the treatment 
option (Craven, 2017). If the target trial time of the medication has been reached by the 





improvement. Methotrexate is the first treatment strategy (Craven, 2017). If methotrexate 
cannot be tolerated, HCQ, leflunomide or sulfasalazine are the next DMARD treatment 
options of choice. ACR/ EULAR classification criteria for RA are based on the efficacy 
of evidential management of RA by a large international task force (Craven, 2017). The 
international task force included several departments of rheumatology all around the 
world that based their decisions, principles, and recommendations on systemic literature 
reviews for therapeutic strategies of RA (Smolen et al., 2017). 
Monotherapy and Combination Therapy in RA 
RA is an autoimmune disease that has a significant negative impact on the ability 
to perform daily activities, work, and household tasks (Singh et al., 2016). The disease 
symptoms need to be treated to prevent further damage to the body. Anti-RA drugs 
consist of DMARDs and/or Biologics. DMARDs can slow the progression of the disease 
by suppressing the body’s overactive immune and inflammatory systems (Cohen et al., 
2019). DMARDs work to decrease the pain severity, reduce the inflammation, prevent 
joint damage, or reduce joint damage, and preserve the structure and function of the joints 
(Cohen et al., 2019). These medications are not designed to provide immediate relief of 
symptoms (Cohen et al., 2019). DMARDs are for long- term use and take weeks to 
months to become active in the body. There are a variety of types of DMARDs. The 
choice of which DMARD to take depends on the following: the stage and severity of the 
condition, the side effects, and the patient’s personal preference which can be driven by 





DMARDs is frequently used as a first-line strategy that can provide a greater therapeutic 
efficacy than monotherapy in some patients, but it has higher toxicity (Wilsdon & Hill, 
2017). Optimal combination of a DMARD with a biologic, and the timing of the 
combination therapy, has been demonstrated to have a superior outcome for some RA 
patients with an inadequate response to methotrexate alone (Wilsdon & Hill, 2017).  
The most used DMARD treatments are methotrexate, sulfasalazine, HCQ, 
leflunomide, and azathioprine (Cohen et al., 2019). Methotrexate was originally designed 
for cancer patients but was found to reduce inflammation and decrease joint damage in 
RA patients (Cohen et al., 2019). It may be combined with other DMARDs or a biologic 
agent if it does not adequately control the disease alone (Cohen et al., 2019). It is the 
recommended first choice of treatment in the guidelines of the ACR and EULAR 
(Wilsdon & Hill, 2017). Sulfasalazine (Azulfidine) is used to treat RA as well as other 
rheumatic autoimmune diseases. It may be combined with other DMARDs or a biologic 
agent if it does not adequately control the disease alone (Cohen et al., 2019). HCQ 
(Plaquenil) was originally developed to treat malaria but was found to improve symptoms 
of arthritis and lupus. It can be used in combination with other DMARDs or a biologic 
(Cohen et al., 2019). Leflunomide (Arava) inhibits production of inflammatory cells to 
reduce inflammation and prevent joint damage from the inflammation (Cohen et al., 
2019). It may be used in combination with DMARDs or with a biologic agent (Cohen et 
al., 2019). Azathioprine (Imuran) was also developed for the treatment of cancer, RA, 





transplantation to prevent rejection of the transplanted organ (Cohen et al., 2019). This 
DMARD is only taken as a combination treatment with methotrexate (Arthritis 
Foundation, 2019). A systematic review using meta-analysis found that DMARDs may 
reduce radiographic erosions, but their long-term use has undesirable effects on the body 
(Wilsdon & Hill, 2017).  
Biologic response modifiers, such as abatacept (Orencia), adalimumab (Humira), 
anakinra (Kineret), baricitinib (Olumiant), certolizumab (Cimzia), etanercept (Enbrel), 
golimumab (Simponi), infliximab (Remicade), rituximab (Rituxan), upadacitinib 
(Rinvoq), tocilizumab (Actemra) and tofacitinib (Xeljanz) all work to target specific 
pathways of the immune system that trigger inflammation (Mayo Clinic, 2019). 
Etanercept, adalimumab, infliximab, certolizumab pegol, and golimumab, are all part of 
the TNF inhibitor class of biologics; and abatacept, rituximab, anakinra, and tocilizumab 
are part of the interleukin kinase inhibitor class of biologics (Cohen et al., 2019). 
Baricitinib, tofacitinib, and upadacitinib all target the JAK pathway. Biologics target 
specific cells that contribute to the manifestation of the disease (Spriggs & Boynes-
Shuck, 2016). Monotherapy biologic medications can increase the risks of infections 
because they work as blocking agents to cytokine activity (Mayo Clinic, 2019). 
Cytokines are used to alert that antigens are present in the body. However, when biologic 
agents are taken as a combination with a DMARD, the risk of infection is reduced, 
because the DMARDS suppress the immune system to reduce the frequency of producing 





discusses benefits, risks, dosing schedule, monitoring frequency and expected results of 
all considered medications for each type of therapy (Cohen et al., 2019). Ongoing 
monitoring is required to identify any potential adverse effects for each patient for safety 
and effectiveness of the treatment (Wilsdon & Hill, 2017). Routine assessments of 
disease activity are essential for the determination of flares that occur with RA (Wilsdon 
& Hill, 2017). Flares are associated with inflammation and pain. Some flares may occur 
from environmental factors that cannot be controlled. Some flares may occur from certain 
foods that cause an inflamed flare-up in the joints. However, constant flares may be due 
to an increased activity of the disease that causes functional deterioration and 
radiographic progression (Wilsdon & Hill, 2017). In this situation, medications may need 
to be increased or potentially changed. To achieve the optimal goal of treatment, the best 
outcomes will come from understanding the therapeutic options available, pre-treatment 
evaluations, follow-up evaluations, and ongoing monitoring for any potential 
complications of the disease or its treatment (Wilsdon & Hill, 2017). 
The development of targeted monoclonal antibodies and small-molecule kinase 
inhibitors has expanded the effective therapeutic options in RA (Wilsdon & Hill, 2017). 
Each of the medications listed in the paragraph above has the ability to modify the 
diseases process to varying extents depending on the individual’s immune response 
(Wilsdon & Hill, 2017). Combination therapy may be used to achieve the optimal results 
for RA relief in some patients, but not all. Combination therapy consists of a DMARD 





biologics can enhance treatment outcomes more than the conventional monotherapy 
approach for some patients that require multiple treatment options. One of the main 
transformations in the way RA is treated is the adoption of an approach whereby the 
activity index of a disease is utilized as a score, a mark to aim at with the therapies. 
Therefore, the approach not only focuses on the reduction score, but also remission or 
low activity of the disease. Setting a treatment target, following the treatment 
recommendations and principles, and applying a sequence of drug strategies, may 
maximize the optimal results. Head-to-head trials comparing the efficacy and safety of 
DMARDs and TNF inhibitors in patients with active RA, despite a trial and/failure of 
methotrexate therapy, are inadequate due to the need for research (Smolen, et al., 2016). 
An expert in RA can only prescribe therapeutic agents for RA. Therefore, it may 
not seem relevant to the primary care, but the rheumatologist and primary care work 
together for the better health of someone with RA. However, general practitioners ought 
to understand the implication of using the drugs and their adverse effects, since they form 
part of the multidisciplinary team that reviews the progress of the disease and its 
treatment options. IL-23 anti-interleukin antibody treatment never reduces the activity of 
the disease by a great margin among RA patients with an inadequate response to 
methotrexate (ACR response 53.6% and 41.3% vs. 40.0% in placebo; Smolen et al., 
2017). The data for the compounds secukinumab and brodalumab (human anti-IL-17 RA 
monoclonal antibodies) that block IL-17 and IL-23 are not effective for some patients in a 





response to the TNF inhibitors improved their immune response using ixekizumab (Taltz) 
because it targeted the interleukin pathway (Genovese et al., 2014). Interestingly, it 
remains contentious whether IL-17 and IL-23 blocking agents might be competitive 
among the already approved and available compounds to treat RA (Genovese et al., 
2014). 
It is important to be evaluated and treated by a rheumatologist to be placed on the 
right treatment regimens. The patient may try several different types of treatment before 
finding the appropriate therapy that provides relief for a better wellbeing. There are 
several factors that contribute to the appropriate treatment plan. The duration and severity 
of the disease, previous treatment restrictions, comorbidities, family planning, 
preferences, and financial and social circumstances are some of the major issues to 
consider when deciding on the appropriate treatment plan (Wilsdon & Hill, 2017). During 
the pre-treatment evaluation, the patient should have baseline blood tests performed that 
include a full blood examination, serum creatinine levels, liver enzyme levels, hepatitis 
screening and TB screening, because abnormalities may alter the choice of therapy and 
dosing (Wilsdon & Hill, 2017). 
EULAR reiterates that biosimilars, which are generic drug therapies, either 
approved by the U.S. Food and Drug Administration (FDA) or the European Medical 
Agency (EMA), report the same safety and efficacy outcomes as the respective biological 
originator, which is the brand name drug therapy (Smolen et al., 2017). Biosimilars 





biologics that were also approved by the EMA in 2017 (Generics and Biosimilars 
Initiative Online, 2017). A significant series of biosimilars is still under development. 
For patients who incur persistent remissions following tapered steroids, tapering 
DMARDs might be a good alternative (Smolen et al., 2017). Injecting patients with 25 
mg etanercept, down from 50 mg per week, or increasing the etanercept or adalimumab 
injection intervals is consistent with tapering medications for the preservation of clinical 
remission or low disease activity, amidst clinically relevant flare rates (Smolen et al., 
2013). Alternatively, abrupt DMARD therapy cessation results in flares among most 
patients, if not all patients. However, not each of those DMARD therapies attain their 
initial remission states or low disease activity. In a recent epidemiological study, 50% of 
the patients involved in an ACT-Ray study stopped using tocilizumab (Actemra) a year 
after sustained clinical remission (Huizinga et al., 2015). However, later in the study, 
84% of the patients suffered recurrent flare-ups and were reintroduced to the tocilizumab 
treatments (Huizinga et al., 2015). Within that double-blind randomized trial, the patients 
under remission with certolizumab pegol (Cimzia) and a DMARD ceased getting 
treatment (Huizinga et al., 2015). Three out of the seventeen patients taking certolizumab 
pegol maintained remission until the 52nd week (Smolen et al., 2015). In accordance with 
EULAR recommendations, when there was particularly persistent remission, tapering the 
DMARDs became a good alternative. However, the recommendation is still under 
investigation because most of the rheumatologists might not cease DMARDs in 





2017). The anti-CCP antibodies should continue being measured in patients with RA or 
suspected RA while taking a combination therapeutic treatment to potentially taper 
medications (Deighton et al., 2009).  
Remission may be achieved through medical interventions and therapeutics 
because bone erosion can be detected in 25% of RA patients within the first 3 months of 
onset of symptoms (Wilsdon & Hill, 2017). In 70% of the RA patients that have not been 
diagnosed with RA, bone erosion may be detected by the third year of painful symptoms 
(Wilsdon & Hill, 2017). Therefore, patients whose RA is detected early and treated 
immediately are less likely to have excessive bone erosion than patients that wait years 
after the symptoms have begun. Delaying treatment beyond 3 months increases joint 
destruction and leads to a higher chance of requiring a more persistent therapy (Wilsdon 
& Hill, 2017). 
RA biological drugs causing infections are on the rise. An estimated 6 out of 
1,000 patients annually are being treated for infections due to biological agents, unlike 
the case of DMARDs (Singh et al., 2015). Future infection prevalence depends on 
glucocorticoid use, comorbidity, age, and history of severe infections as identified in the 
AR-PoWER database. The rise in risks depends on the baseline risks among different 
patient categories (Strangfeld et al., 2011). Therefore, public health surveillances are 
deployed for daily practices to reduce the cases (Lahiri & Dixon, 2015). RCTs associated 
serious inflictions among the biologic augur with the infection rates identified in anti-





were presented and addressed for safety concerns (Singh, Saag, & Bridges, 2016). ACR 
suggests and recommends the use of DMARDs alongside TNF inhibitors, especially 
among patients that have suffered severe infections in the past, despite insufficient 
supporting evidence, because the DMARDs can reduce the infections of TNF biologics 
by reducing the antibodies that respond to the biologic (Lahiri & Dixon, 2015). 
Therefore, biologics may have less risk of infections when taken with a DMARD. RCTs 
have revealed that combination therapy elicits fewer hospitalizations and less severe 
infections (Schiff et al., 2008; Yun et al., 2005). The recommendations do not necessarily 
apply to all patients, as some patients might not want the particular therapy. Therapy 
cannot be forced on patients, but it can be recommended. 
Following TNF inhibitors approval, heart failure cases have lessened when 
infliximab (Remicade) is given to a patient at a dose of 10 mg/kg (Chung et al., 2003). 
Infliximab is a monoclonal antibody that binds to the TNF, so the TNF cannot bind to a 
receptor to trigger immune response. Similarly, the latest studies reveal that heart failure 
never occurs among patients using TNF inhibitors. In fact, symptomatic congestive heart 
failure risk never increases among high-risk patients that endure heart failure, while being 
treated with TNF inhibitors (Emrich, 2009). In a large-scale international study, Bykerk 
and associates reported that subjects using the biologic agent, tocilizumab, while 
remaining on DMARD therapy demonstrated a rapid onset of effect and continued to 





The risk of opportunistic infections in patients being treated with a biological 
DMARD requires these patients to be tested for underlying latent TB (Salliot et al., 
2009). TB reactivation is more prevalent among patients receiving anti-TNF monoclonal 
antibodies, relative to those on etanercept (Enbrel). The membrane-bound TNF plays a 
crucial role in safeguarding a patient against acquiring TB. The TNF antibody neutralizes 
TB, thereby reducing the infection risk (Plessner et al., 2007; Tubach et al., 2009). TNF 
biologics, such as abatacept and rituximab, did not interfere with Mycobacterium 
tuberculosis controls in mice studies (Bigbee et al., 2007). Minor cases of TB occur 
during tofacitinib therapy, and the cases that arise are speculated as new infections the 
patients acquire during clinical trials. The new TB infections manifest among some 
patients because clinical trials take place in a high prevalence zone for the condition 
(Winthrop et al., 2016). Tocilizumab exhibits no TB risk factors in RCTs (Singh et al., 
2016). Before enacting a treatment methodology, determining which DMARDs would be 
best for results, a relevant screening methodology with a TNF inhibitor may be of better 
use (Hua et al., 2004). 
Methotrexate monotherapy results in vaccine impairment. Discontinuing the 
methotrexate for a given period of time perfects the immunogenicity of the influenza 
vaccine among patients suffering from RA (Campbell et al., 2011; Park et al., 2017). 
Tofacitinib elicits little impact regarding vaccine response (Winthrop et al., 2016). TNF 
inhibitors taken with tocilizumab do not lessen the vaccine response (Mori et al., 2013). 





risk. Data obtained from a European study illustrated that perforation in the large 
intestine occurs in tocilizumab patients relative to those who undergo combination 
treatment with DMARDs (Strangled et al., 2017). Large intestinal perforation risk does 
not get resolved despite an improved concomitant glucocorticoid use within Cox 
regression analysis (Strangled et al., 2017). A positive medical history regarding 
diverticulitis contradicts tocilizumab use, meaning that various large intestinal perforation 
issues lack diverticulitis history. Patients need to be aware of large intestinal perforation 
risks and elevated inflammation markers, which may not get interpreted during the 
tocilizumab therapy. 
Lymphoma, non-melanoma and melanoma skin cancers, and other cancers occur 
less frequently among patients using TNF inhibitors relative to patients on the standard 
monotherapy DMARDs (Mercer et al., 2017). A previous study was performed to 
investigate the safety of biologics and DMARDs and found that patients on TNF 
compared to patients on conventional DMARDs did not have an increased risk for 
malignancies in general (Ramiro et al., 2016). Rituximab (Rituxan) is more predominant 
in comorbidities like lymphoproliferative disorders and concomitant multiple sclerosis 
than other biological agents (Mercer et al., 2017). Between 30-40% of the patients with 
RA have poor response to DMARDs (Liu et al., 2017). Therefore, a combination of 
DMARDs together with various action modes of biologics is preferred by some patients. 
Biologics have various roles that target specific areas of the body. TNF, JAK and 





TNF inhibitors reveals the absence of additional benefits, with a minimum of two 
combinations that raise the adverse events like severe infections (Weinblatt et al., 2006; 
Genovese et al., 2004).  
Challenges in RA Management 
There are various challenges regarding the management of RA patients, coupled 
with inefficient responses to the initial standard monotherapy treatment. The increasing 
modes of actions and consequent DMARDs remain core issues still not addressed.  
 Observational data reveals advantages regarding altering the action mode within 
TNF-IR inhibitors by switching to a biologic of a non-TNF. (Greenwald et al., 2011; 
Emery et al., 2015). ACR suggests the application of a non-TNF biological in the event 
of an inadequate response to the initial TNF inhibitor (Singh et al., 2016). In randomized 
control trials and other observational studies, the non-responders to the first DMARD 
therapy gave little clinical response following the conversion to a second trial using a 
TNF inhibitor in co-therapy (Bombardieri et al., 2004; Remy et al., 2011; Schiff et al., 
2014). Cytokines, other than TNFs, might perform disease mediation among primary 
non-responders; and then the patients might experience additional benefits based on 
compounded use of various action modes instead of just TNF blocking (Bombardieri et 
al., 2004; Remy et al., 2011; Schiff et al., 2014). A previous study recommended a 
second TNF inhibitor, or the deployment of agents with different action modes that have 
no hierarchical ranks, was recommended in a case if a TNF inhibitor fails (Rubbert-Roth 





Nearly 60% of patients that switch to a second TNF inhibitor following primary 
failure of the first TNF inhibitor attain a reduction in their disease activity score (DAS)-
28 by a minimum of 1.2 points (Mease et al., 2010). DAS-28 is the 28th version that 
measures disease activity in the 28 joints being examined (NRAS, 2019). The 
examination includes swelling, pain, tenderness, RA specific inflammation markers, x-
rays, and questionnaires (NRAS, 2019). The DAS-28 score is calculated using a unique 
formula. The  scores > 5.1 is high disease activity, < 5.1 is moderate disease activity, < 
3.2 is low disease activity, and < 2.6 is remission (NRAS, 2019). 
Patients who do not respond to TNF inhibitors may require secondary treatment 
measures. Arguably, the medications might have lost response from developing anti-drug 
antibodies, which makes the patient exhibit a clinical non-response to a given anti-genetic 
form of treatment. Data obtained from various randomized controlled placebo trials 
demonstrate safety and efficacy when it comes to TNF alpha inhibitors, such as 
certolizumab (Cimzia), among RA patients under secondary response inadequacy due to 
adverse effects of the first TNF or TNF inhibitor intolerance (Jani et al., 2014). The TNF 
alpha inhibitors block the activity of TNF alpha markers in the body and reduce the TNF 
alpha levels to help decrease the RA symptoms (Ellis & Hein, 2016). Patients who 
develop antibodies during their initial use of a TNF inhibitor are more at risk of 
developing further antibodies upon TNF inhibitors. TNF inhibitors are anti-TNF and can 
cause a rise in antibodies when taken as monotherapy because the immune system is 





DMARD that lowers the antibody response. Immunogenicity might be the primary cause 
of lower clinical efficacy of a second TNF inhibitor as seen in the case of TNF-IR. In this 
scenario, altering the treatment option among patients who exhibit failure on TNF 
inhibitors might be a worthy alternative. For instance, the biologic agents golimumab, 
abatacept, rituximab, tocilizumab, and tofacitinib have been shown to elicit high levels of 
clinical positive response especially among patients that inadequately responded to a 
minimum of one TNF inhibitor (Genovese et al., 2016).  
Direct evaluations of compounds from different action modes in TNF-IR do not 
exist. In addition, there are minimal data available on the safety and efficacy of TNF 
inhibitors following non-TNF-inhibiting DMARDs failure, and a second failure of IL-6 
receptor inhibitor after tocilizumab had failed (Emery et al., 2008). Basically, the choice 
of following a DMARD from TNF-IR is not yet settled upon, apart from EULAR and 
ACR that recommend alternating to non-TNF biologicals in the case where a second TNF 
inhibitor failed (Virkki et al., 2011). 
Apart from the observational data and making indirect comparisons, combination 
therapy comparisons to monotherapy all point to a reduced risk of infections (Rein & 
Mueller, 2017). No consensus has been reached regarding CD20 monoclonal antibody 
applications in patients undergoing rituximab (Rituxan) therapy (Cohen et al., 2006). 
Rituximab is a monoclonal antibody that targets the CD20 b-cells. B-cells play a major 
role in RA because the cytokines are released from the b-cells in response to the 





the body become the foreign antigens. Therefore, an overproduction of inflammation 
occurs that leads to structural damage. The efficacy of b-cell depletion therapy using anti-
CD20 rituximab is a major advance in RA therapy because of the role of b-cells in RA 
pathogenesis (Chen & Cohen, 2012). A collection of safety data has established a well 
safety profile for TNF inhibitors in RA treatments (Rubbert-Roth & Finckh, 2009). 
Abatacept (Orencia) exhibits a relatively accepted safety profile (Schiff et al., 2008). In 
contrast, a meta-analysis indicates an increase in adverse events risk with certolizumab 
pegol (Cimzia) use in the first treatment month (Smolen et al., 2009). RCTs for TNF 
inhibitors seek washout phase of 4 weeks minimum of no treatment after a trial following 
the previous injection or TNF inhibitor infusion (Smolen et al., 2009). ARRIVE, ACT-
SURE, and EXXELARATE are clinical trials that refute the need for the washout phase 
(Smolen et al., 2009). 
Rheumatologists have alternative treatment options to choose from other than 
TNF inhibitors, as well as different action modes and administrative routes. Tocilizumab, 
rituximab and abatacept are generally approved for intravenous access or subcutaneous 
use. Studies which compare the subcutaneous and intravenous administrative routes of 
these treatment agents reveal no major difference in clinical safety and efficacy apart 
from reactions that result at the subcutaneous injection site (Gabay et al., 2013; 
Burmester et al., 2016). Abatacept and rituximab reveals that alternating from a weekly 
subcutaneous TNF injection to intravenous treatments is safe and effective; and might fill 





the patients receiving subcutaneous injections in real life did not feel comfortable 
injecting themselves and preferred intravenous infusions (Mueller et al., 2016). 
Measures Outcome in Rheumatoid Arthritis Therapy 
Within the evaluation of the disease, multiple variables can be dependent or 
independent, whose interpretation often depends on clinical judgment. In a 1994 study, 
with 9 years of follow-up research, the researchers found that reduced educational levels 
correlated with decreased function and increased mortality of RA (Pincus et al., 1994). 
Patients underwent psychological tests and measurements of disability. An attempt was 
made to correlate their psychological state with the disease activity for the patients that 
did not have improving results during the three-year follow-up period (Pincus et al., 
1994). Therefore, RA can affect brain activity. Another study carried out on 122 women 
patients with RA using logistic regression showed that the ability to control work hours 
and family support were variables that contributed to improving the patient’s ability to 
work. 
Another study was conducted with a 2-year follow-up in patients with potential 
predictors of sustained remission for 2 years that observed the DAS-28 and CRP in 
patients using a multivariate analysis (Lee et al., 2017). Age, pain, disease aggression, 
functional disability index obtained from the Health Assessment Questionnaire Disability 
Index, and depression evaluated by the Arthritis Impact Measurement Scales were all 





indicated that Health Assessment Questionnaire (HAQ) scores are useful when stratifying 
RA patients in accordance with their risk for flare-ups (Lee et al., 2017). 
In 2003, a study was done to determine the prognostic factors of disability in early 
RA, as well as the effects on a radiographic scale and the functional course of the disease 
in patients with RA of less than a year who were followed-up for 5 years (Berner et al., 
2018). The study resulted in a high HAQ score correlated with pain, elevated DAS-28, 
higher painful joint counts, and the presence of erosions by the last follow-up (Berner et 
al., 2018). Gender, age, RF scores, IgM or IgA antibodies, and class II genes did not 
contribute significantly to predicting a five-year disability (Pincus et al., 2016). Authors 
suggest that RF may act as an enhancer of bone loss (Van Steenbergen et al., 2015). The 
following year, a systematic review concluded that part of the functional outcome at work 
depends on a biopsychosocial mismatch between the capacity of the individual and the 
demands of work (Pincus et al., 2016). Rheumatologists often use a Multidimensional 
Health Assessment Questionnaire (MDHAQ) and/or a Routine Assessment of Patient 
Index Data to measure the patient’s disease activity and performances on their treatments 
(Chua et al., 2017). Quantitative data from these MDHAQs have provided much valuable 
information for research studies using secondary data (Chua et al., 2017). A benefit of 
using quantitative methodology is to facilitate access to evidence-based secondary data 
rather than primary data (Gopalakrishnan & Ganeshkumar, 2013). According to the ACR 
rates, 20% or greater reported patient improvement in functional disability as reflected by 





Summarization of Therapy 
It should be considered that RA is a potentially catastrophic disease that requires 
energetic management once the diagnosis of the disease has been established. The 
ultimate goal of such treatment is to try to achieve a remission of the disease by putting 
into play the best available therapeutic resources. A particularly important premise for the 
treatment of RA is to start treating the disease as early and as aggressively as possible. 
Several studies have shown that combination therapy using two DMARDs has better 
results than monotherapy DMARDs; and even the combination of three DMARDs may 
be better than two DMARDs (Nocturne et al., 2016). Although treatments using 
DMARDs without a biologic, including combination DMARDS, can be therapeutic for 
the signs and symptoms of the disease, the control is not enough to inhibit the structural 
joint damage for some patients. In those cases, it may be important to consider the use of 
biological agents that have been patient effective, not only for the control of signs and 
symptoms, but also to decrease and inhibit articular damage (Cutolo & Sulli, 2018). 
Over the last 50 years, the treatment strategy of RA was designed on the 
erroneous premise that the prognosis of the disease, in general, was favorable. It is 
currently known that the majority of patients with active RA are clinically disabled 
within the first 20 years of the disease, and that more than 90% of patients with synovitis 
have radiological evidence of erosions in the first 2 years after diagnosis despite 
conventional treatment with Functional Antibiotic Resistance Metagenomic Element 





Although a cure is not a viable goal, remission may be. A proposal for the 
treatment of RA was presented a few years ago in which monotherapy DMARD to be 
used less and less based on growing evidence that biologic agents may be more efficient 
(Cutolo & Sulli, 2018). However, that is not the standard treatment being utilized by 
rheumatologists. Therefore, more research needs to be performed for accuracy. RA 
centers are still overwhelmed with patients performing trial and error on medications. 
This study looked at a comparison of monotherapy and combination treatments using 
biologics at population levels to determine whether there is a difference between 
treatments for Caucasian women between the ages of 30 and 60 years. 
The effectiveness of newly developed biological response modifiers has been 
demonstrated (Olson et al., 2016). The biologic modifiers, TNF, JAK and interleukins, 
target specific cytokines that have an important role in perpetuating the inflammation of 
RA through specific pathways (Ajeganova et al., 2017; Olson et al., 2016). 
Recent information shows that early administration of DMARDs leads to clinical 
improvement and delays in the radiological progression of the disease as it has been 
found to occur with the use of methotrexate, leflunomide, sulfasalazine, HCQ, 
cyclosporine, minocycline, azathioprine, D-penicillamine and intramuscular gold (Tan & 
Smolen, 2016). All share some characteristics, such as the slow start of the action and a 
mechanism of action that is not well elucidated. In a meta-analysis of blinded and 
controlled studies, it was found that the relative potency of the majority of DMARDs 





2016). Compared with methotrexate, leflunomide has similar efficacy for control of 
clinical variables of disease activity and radiological progression (Arntz et al., 2018). 
The literature on combination therapy with DMARDs refers to methotrexate as 
the cornerstone of therapeutic schemes. The first clinical study of combination therapy 
with methotrexate was made in 1995 in patients with partial response to methotrexate at 
the maximum tolerated doses by adding cyclosporin (2.5 to 5 mg/kg) or placebo (Sterne 
et al., 2016). Patients who received both DMARDs had a 25% improvement in both the 
painful joint count compared to the placebo group (p = 0.02); and 25% improvement in 
the count of swollen joints (p = 0.005) compared to the group that received only 
methotrexate (Goodman, 2015). The main toxicity was the increase in serum creatinine 
(Goodman, 2015). 
In another study, 155 adult patients with RA of less than 2 years duration were 
randomized to either combined treatment of prednisolone (60 mg/day), oral methotrexate 
(7.5 mg/semester) and sulfasalazine (2 g/day); or sulfasalazine (2 g/day) as the only 
DMARD (Ter Wee et al., 2017). At week 40, the treatment was similar to week 28. In the 
combination therapy group, the prednisolone had been reduced until it was suspended at 
week 28, and the methotrexate was suspended until week 40 (Ter Wee et al., 2017). The 
researcher wanted to see a change in the RA symptoms by suspending medications. Until 
28 weeks, the sulfasalazine was taken alone, and then after 28 weeks, it was taken in 
combination with the Prednisolone, and then a third DMARD was added at week 40, 





more than the sulfasalazine group alone (Ter Wee et al., 2017). Although the clinical 
improvement was similar after week 28, the radiological benefit (delay of bone damage) 
persisted after five years. The results of this study suggest the concept that using 
glucocorticoids or other medications as induction therapy yields long-term benefits. 
Although glucocorticoids are not included as DMARDs, recent studies have 
demonstrated their ability to slow bone damage in early RA, although the side effects 
limit their use for prolonged periods as monotherapy for the control of RA (Goodman, 
2015). Glucocorticoids in equivalent doses of 10 mg or less of prednisone per day are 
used to treat 30 to 60% of patients with RA (Goodman, 2015). The use of combination 
therapy of DMARDs until less than a decade ago was not so common, but now more than 
30% of RA patients are treated with combination DMARD therapy. This increase has 
been due to the results of studies that demonstrated the additional benefit of adding 
another DMARD to patients on methotrexate with active disease (Cutolo & Sulli, 2018). 
With methotrexate as the only DMARD, one-third of patients improved 50% after 2-4 
years; and the addition of oral folic acid prevented liver toxicity (elevation of 
transaminases) without reducing the efficacy of methotrexate (Cutolo & Sulli, 2018). 
Oral and parenteral therapy of methotrexate has fallen into disuse due to its prolonged 
initiation of intolerable side effects (Taylor et al., 2019). Subcutaneous is the preferred 
method of administration (Taylor et al., 2019). 
There is no cure for RA (Wilson et al., 2004). The present treatments focus on 





DMARDs are the main choice of treatment for RA (Rubbert-Roth & Finckh, 2009). 
Methotrexate was the initial commonly used treatment, and it was effective on standard 
clinical measures of DAS and was cost-effective (Rubbert-Roth & Finckh, 2009). It was 
not well tolerated, however. Biologic agents were a major advance in the treatment of RA 
(Rubbert-Roth & Finckh, 2009). The biologic agents target immune effector cells (T 
lymphocytes, B lymphocytes and macrophages), which are responsible for inflammation 
and structural damage in affected joints, bone, organs and the signaling molecules 
involved in their activation (Rubbert-Roth & Finckh, 2009). TNF inhibitors were the first 
approved biologic agents for the treatment of RA (Rubbert-Roth & Finckh, 2009). TNF 
inhibitors are effective at improving RA symptoms and slowing or preventing structural 
damage (Rubbert-Roth & Finckh, 2009). Biologics are intended to inhibit inappropriate 
cytokine activity and have been used with substantial efficacy to alter the progression of 
RA by targeting cells and molecules that are thought to be functionally important to the 
biologic pathway (Wilson et al., 2004). DMARDs target the entire immune system, and 
biologics target specific areas of the inflammatory process. When taken as a combination, 
DMARDS suppress the immune system to reduce the frequency of the infectious 
antibodies being produced in response to the biologic. In combination, the DMARDs 
lower the antibodies being produced and the biologic targets the specific inflammatory 






Chapter 3: Research Method 
Research and Rationale 
This study compared the therapeutic efficacy of DMARD treatments with a 
biologic to DMARDs without a biologic at population levels for Caucasian Alabamian 
women aged 30 to 60 years that have been diagnosed with RA. The study focused on the 
effectiveness of the two groups, monotherapy DMARD treatments and combination 
treatments with a biologic, for the target population using the following additional 
covariates: age of patient, anti-rheumatic action of treatment, and DAS. Data required for 
answering the stated research question were obtained from the AR-PoWER database 
which was a research network of patients with RA that provides data from patient-
centered research associated with PCORnet (Fleurence et al., 2014). By and large, the 
study was quantitatively built on the tenets of a cross-sectional study in which secondary 
data were used to test the stated hypothesis. 
Methodology 
The study was quantitative. It focused on a cross-sectional study design that was 
used to analyze the association between variables using statistical analyses (Grand 
Canyon University, Center for Innovation in Research and Teaching [CIRT], 2019). The 
methods style was observational and used a predicted hypothesis. Quantitative research 
requires that the statistical data be reliable and measured accurately (CIRT, 2019). This 
methodology used a nominal and ordinal scale of measurement to distinguish between the 





2019). Logistic regression was the statistical method used for this study to analyze the 
relationship between an outcome (dependent variable) and two or more predictors 
(independent variables). Logistic regression is useful in research to explain the 
relationship between the independent variables and the outcome. The model does not 
assume a sequence of random variables, statistical normality, or linearity (Starkweather 
& Moske, 2011). In this study, the three independent variables (predictor variables) were 
the anti-rheumatic actions of treatment (DMARDs with a biologic and DMARDs without 
a biologic), DAS, and age. The dependent variable, which was dichotomous, was the 
therapeutic effectiveness of RA treatments. The control variables were gender, ethnicity, 
and diagnoses.  
Population 
The population was based on location, gender, age, and ethnicity. The population 
data were derived from the AR-PoWER national database that focuses on patients that 
reside in the United States for the purposes of data collection and analysis at population 
levels. Since RA is 2-3 times more common in women than men, the study population 
was composed of women with RA. The age range for this population was 30 to 60 years. 
Although RA can affect all ethnicities, this research was limited to Caucasians. The 
therapeutic efficacy of combining DMARDs and biologics has never been 
comprehensively studied at these population data levels. The rheumatology clinics stay 
full of patients and may take up to a year for initial evaluation. For example, the 





patient visits annually, which is about 80 patients a day, and the majority of the patients 
are women (UAB, 2020).  
Sample Size Estimation  
 The statistical software used for the sample size determination was the g*power 
3.1.9.4 version, as indicated below: 
z tests - Logistic regression 
Options: Large sample  
Analysis: A priori: Compute required sample size  
Input: Tail(s) = One 
 Pr(Y=1|X=1) H1 = 0.1 
 Pr(Y=1|X=1) H0 = 0.2 
 α err prob = 0.05 
 Power (1-β err prob) = 0.95 
 R² other X = 0 
 X distribution = Normal 
 X parm μ = 0 
 X parm σ = 1 
Output: Critical z = -1.6448536 
 Total sample size = 103 
 Actual power = 0.9502378 
 
 The scores of the variables were calculated through a nominal scoring. G*Power 
is a statistical software that was used to calculate effective sample size according to the 
statistical testing that was used. The appropriate testing was contingent on the hypothesis. 
According to the G*Power analysis, this study needed to have 103 total participants to 
have an appropriate sample size with a probability value of 0.05.  The probability value 
determines the statistical significance of the output for each participant data being tested.  
 This study included 100 cases, which consisted of two independent study groups. 





DMARD group). Group 2 included 49 cases using DMARD treatments with a biologic 
(combination DMARD & biologic group). 
Sampling 
 The sampled data collection was of the target population. The database, AR-
PoWER, consisted of secondary data that were randomly selected. The selection was 
performed by stratified random sampling. The data were separated from the bulk 
population into exclusive sub-population sets, such as gender, age, and ethnicity. Once 
the exclusive sub-population parameters were set, the simple random data sampling 
began by obtaining 100 random samples from the stratified random selection of data to 
structure a test group. Stratified random sampling ensures that the subgroups within the 
population provide better coverage of the population because there is more control over 
the subgroups to ensure that all groups are represented in the sampling (Murphy, 2019). 
Stratified random sampling reflects the population being studied more accurately than 
simple random sampling because it divides the population into subgroups, rather than 
merely choosing subjects from an entire population (Murphy, 2019). Choosing from an 
entire population group without parameters can cause potential confounding in the study. 
Data Collection 
 Data were collected through the AR-PoWER national database. The patients had 
already signed consent forms that their results may be used for research, but their 
personal information would not be released. The data used were categorical data that 





improvement while on the medication. The data were specific to the population 
requirements for the study. Therefore, parameters were set for the data according to 
Caucasian women aged 30 to 60. Once the parameters were indicated, the data chosen for 
the study were presented at random according to their treatment plan. There were 50 
cases collected for the monotherapy DMARD group and 50 cases for the combination 
biologic group to perform chi-square statistical testing and logistic regression. 
Operationalization of Constructs 
 This research was quantitative in nature. The quantitative statistical analysis 
involved a small data collection from the data presented to AR-PoWER database from 
actual RA results that were submitted from actual patients. The data used secondary data 
for the purpose of integrating valid and reliable findings in this research (Gopalakrishnan 
& Ganeshkumar, 2013). The statistical test performed for this research was logistic 
regression that models a binary outcome of three independent variable groups in the same 
population: the anti-rheumatic action of treatment (DMARDs with a biologic and 
DMARDs without a biologic), DAS, and age. The actual data for the study were 
secondary data from the national database AR-PoWER, which includes data obtained 
from the UAB Hospital of Rheumatology. The random cases were assigned to the 
conditions based on the above criteria of the baseline characteristics. The data were 
randomly assigned through the national database. A contingency table was formed to 





variable. Each column represented an observational subject with the nominal categorical 
variables. Each row was represented by the individual sample numbered 1-100. 
Statistical Data Analysis 
 Logistic regression was used to predict a nominal dependent variable with 
nominal categorical independent variables (Laerd Statistics, 2018) and any covariates that 
consisted of continuous and nominal variables that related to the dependent variable. The 
dependent variable for this study was the therapeutic effectiveness of RA treatments. The 
dependent variable contained binary nominal categories (No = 0, Yes = 1). The 
covariates for this study were: age of patient, anti-rheumatic action of treatment, and 
DAS. The covariates are the independent variables in a logistic regression model. Each of 
the three independent variables being analyzed were all categorical. All the independent 
variables were entered into the dialog box for covariates because in the Statistical 
Package for the Social Sciences (SPSS) software for logistic regression models, if the 
independent variables relate to the dependent variable, then all will be tested as 
covariates. The values were entered into SPSS for analyzing the dataset to determine an 
outcome (Laerd Statistics, 2018). SPSS was used to compute the data and provide a 
logistic distribution based on the relationship between the independent and dependent 
variables. This statistical model produced parameter estimates that analyze how much 
each predictor variable contributes to the likelihood of the outcome. If the p-value is less 
than or equal to significance level (alpha-α) of 0.05, then the null hypothesis can be 





combination therapy and monotherapy in treating RA patients, and the alternate 
hypothesis is supported (Bruin, 2006). The variables and cases were first entered into a 
crosstab contingency table for the logistic regression model. The 100 test cases were 
entered in rows. The test variables were entered in the columns. A statistical output was 
generated. The regression test provided a predictor model of percentages for the 
DMARDs with and without a biologic that are therapeutically effective. The logistic 
regression provided a classification table that explained how good the model was at 
predicting the outcome. In this study, it represented the percentage of how good the 
model predicated the therapeutic efficacy of the DMARDs with and without a biologic. A 
logistic regression can provide an odds ratio (OR) table that provides the odds of the 
therapeutic effectiveness of DMARDs with a biologic and without a biologic. The higher 
the ratio, the better the odds are for therapeutic efficacy. A model summary was provided 
that detailed the “R squared” percentage that explained how much of the outcome 
(therapeutic effectiveness) was explained by the predictor variables (DMARDs with and 
without a biologic).  
Potential Confounders 
 Potential confounders can cause bias in the data by increasing the variance of the 
dependent variable. Confounders act as additional independent variables that are not 
included in the study. Potential confounders for this study consisted of the year that the 
medication was started, the year the medication was ended, the year that the patient 





performed on women only. Gender was a restricted variable and was not a confounder. 
Whether the patient had insurance and/or a comorbidity may affect the data and be 
permitted as a potential confounder as well. 
Threats to Validity 
 The lack of multiple experimentation may be a threat to the validity of the 
research. Multiple experiments were needed for replication and cross-validation before 
the results can be theoretically interpreted with confidence (Ohlund & Yu, n.d.). 
Therefore, the choice of testing was a factor for internal validity. A potential factor for 
external validity was multiple treatment interference. Patients with RA tried several 
different medications prescribed by the physician for a yearning of pain relief. Therefore, 
the multiple changes in treatment options could have interfered with the effects of the 
current treatment (Ohlund & Yu, n.d.). 
Methods Summary 
 Is there a difference in the therapeutic efficacy of combination DMARD 
treatments with a biologic, compared to monotherapy DMARDs without a biologic, in 
U.S. Caucasian women between the ages of 30 and 60 that have been diagnosed with 
RA? This research may be used for future comparisons with other research at population 
levels to compare differences among populations. The data were collected through the 
AR-PoWER National database for an estimated fifty samples for each treatment group 
(Group 1:  Monotherapy and Group 2:  Combination Therapy). The data were sampled 





test performed was logistic regression that compared the relationship of the two 
independent predictors in the same population to the dependent outcome. There was a 
contingency table to enter the categories for the variables to be analyzed in SPSS. The 
logistic regression generated a comparative analysis among the predictor variables to the 
outcome. Logistic regression and chi-square testing were performed to reduce any 
potential threats to validity through statistical analysis. The comparative analysis using 
logistic regression and chi-square testing were both used for a two-way association 
between the monotherapy treatments and the combination treatments for women patients 
with RA. The logistic regression adjusted for age. 
Hypothesis  
Is there a difference in the therapeutic efficacy of combination DMARD treatments with 
a biologic, compared to monotherapy DMARDs without a biologic, in U.S. Caucasian 
women between the ages of 30 and 60 that have been diagnosed with RA? 
Null Hypothesis: There is no difference in the therapeutic efficacy between 
combination therapy and monotherapy in treating U.S. Caucasian women between the 
ages of 30 and 60 that have been diagnosed with RA. 
Alternative Hypothesis: There is a difference in the therapeutic efficacy between 
combination therapy and monotherapy in treating U.S. Caucasian women between the 






Chapter 4: Results 
Introduction 
The purpose of this study was to compare the therapeutic efficacy of RA 
treatments between monotherapy DMARD drug treatments and combination therapy 
drug treatments in women aged 30 to 60 years. A quantitative methodology was used to 
compare monotherapy treatments to combination therapy treatments using secondary data 
from the AR-PoWER database. The goal was to reveal a variation of differences in the 
forms of treatments (DMARD with a biologic and DMARD without a biologic) as the 
basic formation of statistical analysis. Logistic regression was performed, and it 
presented no association between the effectiveness of the treatments to the anti-rheumatic 
action, such as a monotherapy DMARD or a combination DMARD with a biologic. 
Research Question Analysis 
Is there a difference in the therapeutic efficacy of combination DMARD 
treatments with a biologic, compared to monotherapy DMARDs without a biologic, in 
U.S. Caucasian women between the ages of 30 and 60 that have been diagnosed with 
RA? 
The dependent variable (i.e., the therapeutic effectiveness of RA treatments) and 
the association of the independent variables (i.e., the antirheumatic action of treatment:  
monotherapy DMARD treatments and combination DMARD with biologic treatments, 





Null Hypothesis: There is no difference in the therapeutic efficacy between 
combination therapy and monotherapy in treating U.S. Caucasian women between the 
ages of 30 and 60 that have been diagnosed with RA. 
Alternative Hypothesis: There is a difference in the therapeutic efficacy between 
combination therapy and monotherapy in treating U.S. Caucasian women between the 
ages of 30 and 60 that have been diagnosed with RA. 
The following data sections (data collections, results, and summary) will detail 
the data process further and produce an interpretation of the results.  
Data Collection 
 The data collection began the day after Christmas 2020, 3 days after the IRB data 
approval of the research agreement with Global Healthy Living Foundation (GHLF) for 
the use of their database AR-PoWER. The data obtained from the database were 
consistent with the variables described in Chapter 3. The selection of the data was 
performed by stratified random sampling of 100 cases that were Caucasian women aged 
30 to 60 years. The participants were assigned to the database according to their baseline 
conditions which were women patients diagnosed with RA. The data collection 
originated from the actual RA results submitted from actual patients to the AR-PoWER 
database through the GHLF. The descriptive statistics were calculated using SPSS. A chi-
square test provided an unadjusted two-way association to test the hypothesis. A logistic 





 The categorical dependent variable indicated whether the medication was 
effective as indicated by the patient’s improvement while on the medication. The 
independent variables were categorized by the two groups: monotherapy treatments and 
the combination treatments. The independent variables consisted of the following:  three 
different age groups of patients: 30-39, 40-49, and 50-60; the DAS; and the anti-
rheumatic action of treatment (which was the monotherapy and combination therapy drug 
treatments).  
Results of Descriptive Statistics 
The data consisted of a small sample of 100 cases. There were no missing cases. 
A frequency distribution was analyzed to summarize the measurements of the categorical 
independent variables. There were 100 total cases observed for age of patient (Table 1). 
Out of the 100 cases, 17% were aged 30-39 years, 37% were aged 40-49 years, and 46%  
were aged 50-60 years. 
Table 1 
 
The Proportion of Research Participants by Age Group 
 




30-39 17 17 17 17 
40-49 37 37 37 54 
50-60 46 46 46 100 







Regarding the type of treatment, as seen in Table 2, 51% of the patients used a 
DMARD monotherapy regimen, and 49% of the patients used a biologic regimen with a 
DMARD concurrently. 
Table 2 
The Proportion of Research Participants by the Anti-Rheumatic Action of Treatment 
Anti-rheumatic action 
of treatment 




DMARD monotherapy 51 51 51 51  
    
Biologic combination 
 
49 49 49 100 
Total 100 100 100  
 
The frequency distribution of the DAS can be seen in Table 3. Out of the 100 
cases, 2% scored in remission range with their regimen; 4% scored low disease activity 
with their regimen; 37% scored moderate disease activity with their regimen; and 57% 
scored high disease activity with their regimen. Thus, only 6% of the patients succeeded 
with their regimen to receive the goal of remission to low disease activity. A 
crosstabulation was performed to observe how the DAS was affected by the monotherapy 
DMARD treatments and the combination treatments with a biologic and a DMARD 
(Table 4). Out of the 2% of the patients that scored in the remission range, all were 
treated with a monotherapy DMARD. Out of the 4% of the patients that scored in the low 
disease activity range, only one patient received combination therapy, while the other 





the moderate range, there were 28 patients on combination therapy and 29 patients on 
monotherapy. 
Table 3 
The Proportion of Research Participants by the Disease Activity Score 
 




< 2.6: Disease 
remission 
2 2.0 2.0 2.0 
2.6 – 3.2: Low 
disease activity 
4 4.0 4.0 6.0 
3.2 – 5.1: 
Moderate 
disease activity 
37 37.0 37.0 43.0 
>5.1: High 
disease activity 
57 57.0 57.0 100.0 
















The Cross-Tabulation of the Anti-Rheumatic Action of Treatment & Disease Activity 
Score   































0 1 20 28 49 
      
Total 
frequency 
2 4 37 57 100 
 
Results of Chi-Square Tests 
 A chi-square analysis provided a two-way association between the independent 
variables and the dependent variable. The cross tabulation provided a verification that the 
test itself was consistent with the data. A table was developed (Table 5) that presented a 
relationship between the dependent variable (Effectiveness of Treatment) and the 
independent variable (Age of Patient). Fourteen patients from age group 30-39 stated the 
medications were effective, and three patients stated that the medications were not 
effective. Thirty patients from age group 40-49 stated that the medications were effective, 
and seven patients stated that the medications were not effective. Thirty-nine patients 
from age group 50-60 stated that the medications were effective, and seven patients stated 





Pearson value of 0.205 indicated that there was not much association. The p-value was 
0.902 which was above the alpha level of 0.05.  I failed to reject the null hypothesis that 
there is no difference between the combination therapy and monotherapy in treating RA 
patients based on the lack of association of the effectiveness of treatments and the ages of 
the patients. 
Table 5 
The Cross-Tabulation of the Effectiveness of Treatment & Age of Patient 
   
  Age group: 
30 - 39 
Age group: 
40 - 49 
Age group: 











No 3 7 7 17 
      
Total  17 37 46 100 
 
Table 6 
The Chi-Square Test: Effectiveness of Treatment & Age of Patient 
 
Value            DF P-Value 
 
Pearson chi-square .205 2 .902  
Likelihood ratio .205 2 .902  
N of valid cases 100    
* 1 cell (16.7%) have expected count less than 5. The minimum expected count was 2.89.  






A cross-tabulation was developed (Table 7) that presented a relationship between 
the dependent variable (Effectiveness of Treatment) and the independent variable (Anti-
Rheumatic Action of Treatment). Forty-four patients stated the DMARD monotherapy 
treatments were effective, and seven patients stated that the DMARD monotherapy 
treatments were not effective. Thirty-nine patients stated the biologic combination 
treatments were effective, and 10 patients stated that the biologic combination treatments 
were not effective. Thus, 83% of the patients stated that their regimen was effective, 
whether it be monotherapy DMARD treatments or biologic combination treatments. 
Table 8 provides the chi-square analysis. The Pearson value, which was 0.791,  indicated 
there was some variation and slight association. However, the p-value was 0.374 which 
was above the alpha level of 0.05.  Therefore, I failed to reject the null hypothesis for the 
association of the effectiveness of treatments and the anti-rheumatic action of treatment.  
Table 7 
The Cross-Tabulation of the Effectiveness of Treatment & Anti-Rheumatic Action of 
Treatment 















No  7 10 17 
      






The Chi-Square Test:  Effectiveness of Treatment & Anti-Rheumatic Action of Treatment 
 







Pearson chi-square .791 1 .374    
Likelihood ratio .794 1 .373    
Continuity 
correction 
.388 1 .533    
Fisher’s exact test    .432 .267  
N of valid cases 100      
* 0 cells (0.0%) have expected count less than 5. The minimum expected count was 8.33. 
 
Results of Logistic Regression Model 
A logistic regression was performed to determine whether there was an 
association between the type of RA drug treatment and its effectiveness. The dependent 
variable was the outcome, the effectiveness of the treatments. The dependent variable 
was coded categorically according to the effectiveness: 0 = no, 1 = yes. The independent 
variables were indicated as covariates in SPSS. There were three independent variables. 
The first independent variable was categorized according to the anti-rheumatic action of 
the drug treatment: the DMARD monotherapy drug treatments and the combination 
biological drug treatment with a DMARD. Another independent variable was  age of the 
individuals set in three age groups: 30-39 (n=17),  40-49 (n=37), and 50-60 (n=46). The 
last independent variable was the DAS which was measured by the swelling and achiness 





with low disease activity), 2 = score 3.2 – 5.1 (patient with moderate disease activity), 
and 3 = score >5.1 (patient with high disease activity).  
The log likelihood summary contains the R² statistic which provides 
representation that the model is a good fit for the data. The “Cox and Snell R Square” 
calculated the variation among the independent variables in association with the 
dependent variables. The “Nagelkerke R Square” measures the same and is typically 
between 0 and 1.  The Cox and Snell are usually more conservative with the calculation. 
According to the model summary, there was a 4 – 6.8% variation that explained the 
therapeutic efficacy of RA treatments among the three independent variables. Therefore, 
the model built for this study did fit the data. However, the stronger the model, the higher 
the R² statistic. An algorithm was computed for the likelihood ratio (LR) = 87.050.  
Therefore, the model did hold true to provide an estimation of “good enough” fit for the 
data. 
The Hosmer and Lemeshow Test is a goodness-of-fit statistical test. This test 
works well for variables with a binary response. As in this study, there was a binary 
response of “yes” the treatment was effective or “no” the treatment was not effective. 
Hosmer and Lemeshow tests are used in logistic regression to measure whether a model 
is satisfactory for the study. The significant value determines if the model is a poor fit if, 
p < 0.050.  The significant value for this study was > 5%; p < 0.585.  Therefore, this 





 The logistic regression model provided details as to whether or not the model had 
a significant association between the effectiveness of the treatments and the predictor 
independent variables. The coefficients of the model were labeled “B”. A positive 
coefficient with a p ≤ 0.050 would indicate a positive association between the variables. 
The data in Table 9 did not support a significant association between the predictor 
variables and the outcome variable. In standard regression coefficients (B), the null 
hypothesis must have a value ≤ 0 in a population; and the alternative hypothesis would 
have a value > 0. The coefficients for the logistic regression in this study were < 0 and 
supported the null hypothesis. In addition, the coefficients were also the log odds that 
relate to the linearity of the independent variables (Table 9).  
The OR of the model was labeled “Exp. B”. In a standard regression, if OR = 1, 
then there is no relationship between the independent and dependent variables. If the odds 
ratio is > or < 1, then there could be a potential relationship between the variables. The 
age of the patient OR = 1.150, which could have a potential relationship with the 
dependent variable. The action of treatment OR = 0.638, and the DAS OR = 0.480, which 
are both < 1, which could mean that there was a potential relationship between the 
independent variables and the dependent variable. However, the significant value of the 
variables was > 0.050 which indicated there was no association.  
The 95% confidence interval (C.I.) is useful for hypothesis testing. In a standard 





hypothesis. As in this study, the 95% C.I. for each of the predictor variables supported 
the null hypothesis.  
 Logistic regression requires no multicollinearity (strong correlation) among 
independent variables. This can be measured is SPSS by observing the collinearity 
diagnostics of the independent variables. The collinearity of two or more scale 
independent variables must be tested and tested again in reverse order to measure for any 
strong correlation. The threshold for the variance inflation factor (VIF) is 3. Therefore, 
any VIF greater than 3 may potentially have multicollinearity issues. The VIF for this 
study was 1.000 for each of the two variables tested. Also, there were not many 
independent variables for this study, thus decreasing the probability of multicollinearity.  
Table 9 
The Logistic Regression Model – Variables in the Equation 
 
















-.735 .519 2.004 1 .157           .480 .173  1.327 
Constant 3.550 1.513 5.505 1 .019         34.798    






 The purpose of this study was to compare the effects of the DMARD 
monotherapy drug treatments and the biologic combination drug treatments with a 
DMARD. The Cox and Snell R², Nagelkerke R², and Hosmer and Lemeshow Tests are 
all in agreement that the model fits the data. However, according to the data in relation to 
the statistical associations of variables, there was no significant evidence that supported 
the alternative hypothesis. The logistic regression coefficients in the model were < 0. The 
null hypothesis had been failed to be rejected. The 95% C.I. was in the appropriate range 
for null hypotheses. The chi-square models also supported the null; there was no 
association between the variables. The null hypothesis was not rejected in any of the 
tests. In lieu of all the evidence, there was no significant difference in the therapeutic 
efficacy of RA treatments. The monotherapy drug treatments were no more or less 
effective than the combination therapy drug treatments, according to the logistic 
regression model. The logistic regression model met all requirements for the analysis to 
test the hypothesis. The research question, “Is there a difference in the therapeutic 
efficacy of combination DMARD treatments with a biologic, compared to monotherapy 
DMARDs without a biologic, in U.S. Caucasian women between the ages of 30 and 60 
that have been diagnosed with RA?”, was answered by there was no significant 
difference in the drug treatments for RA. RA is an autoimmune disease that will affect 
each individual differently. The medications that are prescribed will respond to each 





Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
The purpose of this study was to compare the therapeutic efficacy of RA 
treatments between monotherapy DMARD and combination therapy of DMARD plus 
biologic using quantitative statistical analysis. The goal was to reveal a variation of 
differences in the forms of treatments as the basic formation of statistical analysis. The 
chi-square tests and the logistic regression generated a comparative analysis among the 
predictor variables to the outcome variable. The chi-square test results were important for 
testing the hypothesis in addition to the logistic regression model. While the chi-square 
tests provided an unadjusted two-way association, the logistic regression model observed 
the same association, but adjusted for age. The p-value for the chi-square tests did not 
significantly indicate an association, and I therefore did not reject the null hypothesis. 
The logistic regression model also reported a low statistical power in failing to reject the 
null hypothesis.  
Previous research investigated the safety of biologics and DMARDs and observed 
the clinical patient responses to the medications individually. Previous studies identified 
prognostic factors of RA and calculated their disease activity. I conducted a quantitative 
correlational design to analyze the association between predictor variables and the 
outcome variable using statistical analyses of secondary data. Correlation designs are an 
observation of data collection and not for cause and effect (CIRT, 2019). This methods 
style was observational and uses a predicted hypothesis. The chi-square tests are 





explains the relationship between the variables. In this study, the three independent 
variables (predictor variables) were the anti-rheumatic actions of treatment (DMARDs 
with a biologic and DMARDs without a biologic), DAS, and age. The dependent variable 
was indicated as the therapeutic effectiveness of RA treatments. There was no statistical 
association between these variables in this study.  
Interpretation of the Findings 
 This study was conducted on 100 RA data cases. There were two sub-groups that 
were used as predictor variables. The monotherapy DMARD sub-group contained 51 
cases, and the combination biologic and DMARD sub-group contained 49 cases. A 
sample size estimation was performed prior to the analysis using the G*power statistical 
software 3.1.9.4 version. The analytical software indicated an estimation of 103 data 
cases was needed for the study. Therefore, the total number of cases was slightly under 
the estimated recommendation by three cases. 
 A chi-square test was performed to evaluate a possible association between the 
effectiveness of the treatment (dependent variable) and the age of the patient 
(independent variable). The test was not statistically significant with p = 0.902. I failed to 
reject the null hypothesis. A chi-square test was performed to evaluate a possible 
association between the effectiveness of the treatment (dependent variable) and the anti-
rheumatic action of treatment (independent variable). The test was not statistically 





not able to be performed on DAS (independent variable) because it was continuous data; 
it contained interval data that was measured according to a scale.  
 The statistical analysis for this study found no association between the dependent 
variable and the independent variables. Therefore, there was no significant difference 
between the monotherapy treatments and combination treatments for the therapeutic 
effectiveness for RA. The results of this study were not consistent with the research 
findings of other researchers, such as Cutolo and Sulli (2018), who were observing 
osteoclastic functioning of RA patients using biologic DMARD therapy. However, the 
results of this study were consistent with the research findings of Parida et al. (2015) who 
were comparing the efficacy and infectious side effects of non-biologics versus biologics. 
Those researchers found that monotherapy, combination therapy, and triple therapy of 
non-biologics (DMARDs) were similar to the efficacy of combination anti-TNF biologic 
agents with methotrexate, and this was observed across various populations (Parida et al., 
2015).  
 This research did not support the idea that combination drug treatments using a 
DMARD, and a biologic agent are more effective than monotherapy DMARD treatments 
for the population studied. In fact, the results of the logistic regression and chi-square 
testing of this study provided evidential support that there is no difference in the 
treatments for the specific population of Caucasian women aged 30 to 60 years. The p-
values for these tests were not significant and therefore indicated no association between 





coefficients for the logistic regression in this study were < 0 and supported the null 
hypothesis. 
Limitations of the Study 
 Limitations are characteristic constraints that result in unanticipated challenges 
within the study. There were several limitations to this study that needed to be addressed. 
One limitation was that this study was conducted using secondary data. The data were 
patient reported to the GHLF and incorporated into the AR-PoWER Database. Most of 
the data were obtained from a large source, the UAB Rheumatology Hospital in 
Birmingham, Alabama. However, the database is a national database, and I was not able 
to determine that all the data came from UAB as opposed to from another rheumatology 
clinic. A second limitation is that the data observed Caucasian women only and was not 
compared to other ethnicities or gender. A third limitation was the sample size. The 
sample size of 100 cases was slightly smaller than recommended. A larger sample size 
could potentially provide more precision. A fourth limitation was in the methodology. 
More independent variables could have possibly yielded different results. However, there 
was limited access to the specifics of the secondary data, such as the time the medications 
were tried and stopped, as well as the location of the patient, which resulted in 
unavailability of further data. The only data that was available was the gender, race, 
disease activity score, medication taken, and if it was stopped or continued. A fifth 
limitation is that the participants had comorbidities that altered their DAS. However, this 





Recommendations for Further Study 
 The findings of this study may help enhance the knowledge on how to 
appropriately use DMARD and biologic treatments to control the inflammatory response 
to prevent severe bone erosion and joint deformity. The literature may provide 
knowledge on potential comorbidities that follow the autoimmune disease, such as 
cardiovascular and pulmonary diseases. The statistical analysis may close the gap in 
literature for Caucasian women ages 30 to 60 years on the therapeutic efficacy of 
DMARD treatments that stop the inflammatory cells from being produced and the 
biologic treatments that stop the immune system from being overactive. Although 
combination biologic DMARD therapy may work well together for some RA patients, it 
is not a standard treatment for all patients. According to the results of this study, there 
was no difference in the therapeutic efficacy between combination therapy and 
monotherapy in treating U.S. Caucasian women between the ages of 30 and 60 years that 
have been diagnosed with RA. Public health, insurance providers and physicians are the 
ones that design the policies of standard regimen for diseases. This research can possibly 
make an impact on their policies of treatments for patients being diagnosed with RA. The 
findings of this study may help bring social change by providing evidence as related to 
the efficacy of combination therapy for RA, compared to the standard monotherapy 
treatment, which would be valuable in developing more effective clinical and/or public 
health practices for healthcare policy regulations to ensure regulatory standards are being 





broaden the research by comparing data from other ethnicities and gender. I would also 
recommend incorporating comorbidities to see if it would influence the findings of the 
study. A retrospective cohort study would be recommended to incorporate time analysis 
as well as comparative analysis. 
Implications for Positive Social Change 
 The purpose of this study was to compare the therapeutic efficacy of RA 
treatments. A positive social change implication of this study’s findings is that the 
assessment of the efficacy of DMARDs with a biologic agent and DMARDs without a 
biologic agent may warrant further investigation in which studies with large sample sizes 
that include various populations are used. In this study, there was no difference between 
the monotherapy and combination therapy treatments for Caucasian women aged 30 to 60 
years. The findings of this study did not influence medical policies for public health 
issues on the effectiveness of combination therapeutics as the potential RA standard 
regimen.  
 It is apparent that the prescribed treatments for the autoimmune disease will 
respond to each individual’s cellular structure differently. Biological agents are made in a 
laboratory from living organisms. These agents target specific cellular pathways in the 
body. Each RA patient will have inflammatory responses due to various reasons whether 
it be environmental, infectious, genetic, or hormonal. There is not a specific RA test that 
determines which type of biologic is needed, so it is trial and error. For example, 





receptor to interrupt the pathway. However, if the patient’s RA is not flaring from 
inflammation in the interleukin pathway, that biologic will not work. Then, the patient 
must wait for the medications half-life or until the medication has exited from the 
bloodstream. Conventional DMARDs are immunosuppressive agents. These drugs are 
initial treatments because they have less severe side effects on the body. DMARDs are 
good for long-term use, but do not activate as quickly as a biologic. The disease activity 
and severity, comorbidities, allergies, and even patient preference (including cost, oral 
administration versus injection administration, and frequency of monitoring) all play a 
pivotal role in the determination of DMARD therapy (Benjamin, Bansal, Goyal &Lappin, 
2020). However, all DMARDs work the same by suppressing inflammatory responses no 
matter the pathway. 
Conclusion 
 RA is an autoimmune disease that can attack the entire body through 
inflammation. DMARD treatments target the entire immune system, whilst biologics 
target specific areas of the inflammatory process. When taken as a combination, the 
DMARD can suppress the immune system to reduce the frequency of the infectious 
antibodies being produced in response to the biological agent. This occurrence is relevant 
for combination treatments because the DMARDs lower the antibodies being produced 
while biologic agents target specific inflammatory sites, such as TNF or interleukins, by 
working a blocking agent. However, the results for this study did not find a significant 





monotherapy treatments or the combination action of treatment. Having adjusted for age, 
logistic regression was used to examine the association between the therapeutic 
effectiveness and the treatment modality (DMARDs without a biological agent and 
DMARDs with a biologic agent) with an OR > 1 for age; OR < 1 for DAS and action of 
treatment; all of which had a potential relationship with the dependent variable. 
Therefore, the action of treatment, DMARD with a biologic and DMARD without a 
biologic, had < 1% effectiveness on a therapeutic outcome. However, the significant 
value result indicated that there was no significant association between treatment 
effectiveness and treatment modality. Therefore, according to the statistical findings of 
this study, the combination drug treatments were no more or less effective than the 
monotherapy therapy drug treatments. The effectiveness of the treatment depends on the 
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